Title: HOUSE BILL NO. 2584 By: Hilbert
Official Title: HOUSE BILL NO. 2584 By: Hilbert
Number of Sections: 2
Source: versions - Policy Committee Recommendation
Media Type: application/pdf
Strikethrough Detection: 45 sections found

================================================================================

Section 1:
1 STATE OF OKLAHOMA
2 1st Session of the 60th Legislature (2025)
3 POLICY COMMITTEE
RECOMMENDATION
4 FOR
5
6
7
8 POLICY COMMITTEE RECOMMENDATION
9 An Act relating to physician assistants; amending 59
O.S. 2021, Section 353.1a, which relates to the
10 Oklahoma Pharmacy Act; clarifying which prescriptions
for controlled dangerous substances pharmacists may
11 dispense; amending 59 O.S. 2021, Sections 519.2,

Section 2:
519.3, 519.6, 519.11, as amended by Section 1,
12 Chapter 164, O.S.L. 2022, and 521.2 (59 O.S. Supp.
2024, Section 519.11), which relate to the Physician
13 Assistant Act; modifying definitions; increasing the
number of Physician Assistant Committee members;
14 clarifying certain requirements for the chair;
increasing member requirements for a quorum; adding
15 provisions regarding postgraduate clinical practice;
clarifying filing requirements for practice
16 agreements; clarifying language regarding practicing
medicine, prescribing drugs, and using medical
17 supplies under a practice agreement; modifying
billing and payment authority; amending 63 O.S. 2021,
18 Section 1-317, as last amended by Section 133,
Chapter 452, O.S.L. 2024 (63 O.S. Supp. 2024, Section
19 1-317), which relates to the Oklahoma Public Health
Code; clarifying the authority of physician
20 assistants to carry out certain functions; amending
63 O.S. 2021, Sections 2-101, as last amended by
21 Section 1, Chapter 308, O.S.L. 2024, and 2-312, as
amended by Section 2, Chapter 184, O.S.L. 2022 (63
22 O.S. Supp. 2024, Sections 2-101 and 2-312), which
relate to the Uniform Controlled Dangerous Substances
23 Act; modifying definitions related to physician
assistants; clarifying which physician assistants may
24 prescribe and administer certain controlled
Req. No. 12904 Page 1
1 substances; repealing 59 O.S. 2021, Section 521.4,
which relates to physician supervision and practice
2 agreements; and declaring an emergency.
3
4
5 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
6 SECTION 1. AMENDATORY 59 O.S. 2021, Section 353.1a, is
7 amended to read as follows:
8 Section 353.1a A. Prescribing authority shall be allowed,
9 under the medical direction of a supervising physician, for an
10 advanced practice nurse recognized by the Oklahoma Board of Nursing
11 in one of the following categories: advanced registered nurse
12 practitioners, clinical nurse specialists, or certified nurse-
13 midwives. The advanced practice nurse may write or sign, or
14 transmit by word of mouth, telephone or other means of communication
15 an order for drugs or medical supplies that is intended to be
16 filled, compounded, or dispensed by a pharmacist. The supervising
17 physician and the advanced practice nurse shall be identified at the
18 time of origination of the prescription and the name of the advanced
19 practice nurse shall be printed on the prescription label.
20 B. Pharmacists may dispense prescriptions for non-controlled
21 prescription drugs authorized by an advanced practice nurse or
22 physician assistant, not located in Oklahoma, provided that they are
23 licensed in the state in which they are actively prescribing.
24
Req. No. 12904 Page 2
1 C. Pharmacists may only dispense prescriptions for controlled
2 dangerous substances prescribed by an:
3 1. An advanced practice nurse or physician assistant licensed
4 in the State of Oklahoma and supervised by an Oklahoma-licensed
5 practitioner; or
6 2. A physician assistant licensed in the State of Oklahoma and
7 supervised by an Oklahoma-licensed practitioner.
8 SECTION 2. AMENDATORY 59 O.S. 2021, Section 519.2, is
9 amended to read as follows:
10 Section 519.2 As used in the Physician Assistant Act:
11 1. "Board" means the State Board of Medical Licensure and
12 Supervision;
13 2. "Committee" means the Physician Assistant Committee;
14 3. "Practice of medicine" means services which require training
15 in the diagnosis, treatment and prevention of disease, including the
16 use and administration of drugs, and which are performed by
17 physician assistants so long as such services are within the
18 physician assistants' skill,. For a physician assistant required to
19 practice under supervision of a delegating physician, services form
20 a component of the physician's scope of practice, and are provided
21 with physician supervision, including authenticating by signature
22 any form that may be authenticated by the delegating physician's
23 signature with prior delegation by the physician;
24
Req. No. 12904 Page 3
1 4. "Patient care setting" means and includes, but is not
2 limited to, a physician's office, clinic, hospital, nursing home,
3 extended care facility, patient's home, ambulatory surgical center,
4 hospice facility or any other setting authorized by the delegating
5 physician;
6 5. "Physician assistant" means a health care professional,
7 qualified by academic and clinical education and licensed by the
8 State Board of Medical Licensure and Supervision, to practice
9 medicine with physician supervision as a physician assistant;
10 6. 5. "Delegating physician" means an individual holding a
11 license in good standing as a physician from the State Board of
12 Medical Licensure and Supervision or the State Board of Osteopathic
13 Examiners, who supervises one or more physician assistants and
14 delegates decision making pursuant to the practice agreement;
15 7. 6. "Supervision" means overseeing or delegating the
16 activities of the medical services rendered by a physician assistant
17 through a practice agreement between a medical doctor or osteopathic
18 delegating physician performing procedures or directly or indirectly
19 involved with the treatment of a patient, and the physician
20 assistant working jointly toward a common goal of providing
21 services. Delegation shall be defined by the practice agreement.
22 The physical presence of the delegating physician is not required as
23 long as the delegating physician and physician assistant are or can
24 be easily in contact with each other by telecommunication. At all
Req. No. 12904 Page 4
1 time s a physician assistant required to practice under supervision
2 shall be considered an agent of the delegating physician;
3 8. 7. "Telecommunication" means the use of electronic
4 technologies to transmit words, sounds or images for interpersonal
5 communication, clinical care (telemedicine) and review of electronic
6 health records; and
7 9. 8. "Practice agreement" means a written agreement between a
8 physician assistant and the a delegating physician concerning the
9 scope of practice of the physician assistant to only be determined
10 by the delegating physician and the physician assistant based on the
11 education, training, skills and experience of the physician
12 assistant. The agreement shall involve the joint formulation,
13 discussion and agreement on the methods of supervision and
14 collaboration for diagnosis, consultation and treatment of medical
15 conditions and shall include the scope of and any limitations on
16 prescribing. A practice agreement is required for a physician
17 assistant as described in subsection C of Section 519.6 of this
18 title.
19 SECTION 3. AMENDATORY 59 O.S. 2021, Section 519.3, is
20 amended to read as follows:
21 Section 519.3 A. There is hereby created the Physician
22 Assistant Committee, which shall be composed of seven (7) nine (9)
23 members. Three Five members of the Committee shall be physician
24 assistants appointed by the State Board of Medical Licensure and
Req. No. 12904 Page 5
1 Supe rvision from a list of qualified individuals submitted by the
2 Oklahoma Academy of Physician Assistants. One member shall be a
3 physician appointed by the Board from its membership. One member
4 shall be a physician appointed by the Board from a list of qualified
5 individuals submitted by the Oklahoma State Medical Association and
6 who is not a member of the Board. One member shall be a physician
7 appointed by the State Board of Osteopathic Examiners from its
8 membership. One member shall be a physician appointed by the State
9 Board of Osteopathic Examiners from a list of qualified individuals
10 submitted by the Oklahoma Osteopathic Association and who is not a
11 member of said board.
12 B. The term of office for each member of the Committee shall be
13 five (5) years.
14 C. The Committee shall meet at least quarterly. At the initial
15 meeting of each calendar year, the Committee members shall elect a
16 chair from the physician assistant members. The chair or his or her
17 designee shall represent the Committee at all meetings of the Board.
18 Four Five members shall constitute a quorum for the purpose of
19 conducting official business of the Committee.
20 D. The State Board of Medical Licensure and Supervision is
21 hereby granted the power and authority to promulgate rules, which
22 are in accordance with the provisions of Section 519.1 et seq. of
23 this title, governing the requirements for licensure as a physician
24 assistant, as well as to establish standards for training, approve
Req. No. 12904 Page 6
1 inst itutions for training, and regulate the standards of practice of
2 a physician assistant after licensure, including the power of
3 revocation of a license.
4 E. The State Board of Medical Licensure and Supervision is
5 hereby granted the power and authority to investigate all
6 complaints, hold hearings, subpoena witnesses and initiate
7 prosecution concerning violations of Section 519.1 et seq. of this
8 title. When such complaints involve physicians licensed by the
9 State Board of Osteopathic Examiners, the State Board of Osteopathic
10 Examiners shall be officially notified of such complaints.
11 F. 1. The Committee shall advise the Board on all matters
12 pertaining to the practice of physician assistants.
13 2. The Committee shall review and make recommendations to the
14 Board on all applications for licensure as a physician assistant and
15 all applications to practice which shall be approved by the Board.
16 When considering applicants for licensure, to establish standards of
17 training or approve institutions for training, the Committee shall
18 include the Director, or designee, of all Physician Assistant
19 educational programs conducted by institutions of higher education
20 in the state as members.
21 3. The Committee shall assist and advise the Board in all
22 hearings involving physician assistants who are deemed to be in
23 violation of Section 519.1 et seq. of this title or the rules of the
24 Board.
Req. No. 12904 Page 7
1 SECTION 4. AMENDATORY 59 O.S. 2021, Section 519.6, is
2 amended to read as follows:
3 Section 519.6 A. No health care services may be performed by a
4 physician assistant unless a current license is on file with and
5 approved by the State Board of Medical Licensure and Supervision.
6 B. A physician assistant with six thousand two hundred forty
7 (6,240) or more hours of postgraduate clinical practice experience
8 who has reported those hours to the Board shall not be required to
9 practice under the supervision of a delegating physician.
10 1. A physician assistant may report the completion of
11 postgraduate clinical practice experience to the Board at any time
12 after completion of at least six thousand two hundred forty (6,240)
13 such hours.
14 2. Hours earned prior to the enactment of this subsection shall
15 be counted towards the six thousand two hundred forty (6,240) hours.
16 3. The Board shall maintain, make available, and keep updated,
17 on the Internet website of the Board, a list of physician assistants
18 who have reported completion of six thousand two hundred forty
19 (6,240) or more postgraduate clinical practice experience hours.
20 4. The Board shall, within ninety (90) days of enactment,
21 prescribe a form for reporting postgraduate clinical practice
22 experience by a physician assistant. The Board shall make available
23 and keep updated on the Internet website of the Board the prescribed
24 form. This reporting form may be filed electronically. The Board
Req. No. 12904 Page 8
1 shal l not charge a fee for reporting hours or filing of the
2 prescribed form.
3 5. Nothing in this subsection shall prohibit a physician
4 assistant from maintaining a practice agreement; however, such an
5 agreement is not required for a physician assistant with the
6 reported six thousand two hundred forty (6,240) hours of
7 postgraduate clinical practice experience, provided any practice
8 agreements are subject to the requirements of paragraphs 1, 2, 3,
9 and 4 of subsection C of this section.
10 6. Nothing in this subsection shall restrict the ability of the
11 Board to require supervision as a part of disciplinary action
12 against the license of a physician assistant.
13 C. A physician assistant with less than six thousand two
14 hundred forty (6,240) hours of postgraduate clinical practice
15 experience or who has completed six thousand two hundred forty
16 (6,240) hours but has not reported those hours to the Board shall
17 practice under the supervision of a delegating physician with the
18 following requirements:
19 1. All practice agreements and any amendments shall be filed
20 with the State Board of Medical Licensure and Supervision within ten
21 (10) business days of being executed. Practice agreements may be
22 filed electronically. The State Board of Medical Licensure and
23 Supervision shall not charge a fee for filing practice agreements or
24 amendments of to practice agreements.;
Req. No. 12904 Page 9
1 B. 2. A physician assistant may have practice agreements with
2 multiple allopathic or osteopathic physicians. Each physician shall
3 be in good standing with the State Board of Medical Licensure and
4 Supervision or the State Board of Osteopathic Examiners.;
5 C. 3. The delegating physician need not be physically present
6 nor be specifically consulted before each delegated patient care
7 service is performed by a physician assistant, so long as the
8 delegating physician and physician assistant are or can be easily in
9 contact with one another by means of telecommunication. In all
10 patient care settings, the The delegating physician shall provide
11 appropriate methods of participating in health care services
12 provided by the physician assistant including:
13 a. being responsible for the formulation or approval of
14 all orders and protocols, whether standing orders,
15 direct orders or any other orders or protocols, which
16 direct the delivery of health care services provided
17 by a physician assistant, and periodically reviewing
18 such orders and protocols,
19 b. regularly reviewing the health care services provided
20 by the physician assistant and any problems or
21 complications encountered,
22 c. being available physically or through telemedicine or
23 direct telecommunications for consultation, assistance
24 with medical emergencies or patient referral,
Req. No. 12904 Page 10
1 d. reviewing a sample of outpatient medical records.
2 Such reviews shall take place at a site agreed upon
3 between the delegating physician and physician
4 assistant in the practice agreement which may also
5 occur using electronic or virtual conferencing, and
6 e. that it remains clear that the physician assistant is
7 an agent of the delegating physician; but, in no event
8 shall the delegating physician be an employee of the
9 physician assistant.;
10 D. 4. In patients with newly diagnosed complex illnesses, the
11 physician assistant shall contact the delegating physician within
12 forty-eight (48) hours of the physician assistant's initial
13 examination or treatment and schedule the patient for appropriate
14 evaluation by the delegating physician as directed by the physician.
15 The delegating physician shall determine which conditions qualify as
16 complex illnesses based on the clinical setting and the skill and
17 experience of the physician assistant.
18 E. 1. D. A physician assistant under the direction of a
19 delegating physician not practicing under a practice agreement may
20 prescribe written and oral prescriptions and orders. The physician
21 assistant not practicing under a practice agreement may prescribe
22 medical supplies, services, and drugs, including controlled
23 medications in Schedules II III through V pursuant to Section 2-312
24 of Title 63 of the Oklahoma Statutes, and medical supplies and
Req. No. 12904 Page 11
1 serv ices as delegated by the delegating physician and as approved by
2 the State Board of Medical Licensure and Supervision after
3 consultation with the State Board of Pharmacy on the Physician
4 Assistant Drug Formulary. Physician assistants not practicing under
5 a practice agreement may not dispense drugs, but may request,
6 receive, and sign for professional samples and may distribute
7 professional samples to patients.
8 2. A physician assistant may write an order for a Schedule II
9 drug for immediate or ongoing administration on site. Prescriptions
10 and orders for Schedule II drugs written by a physician assistant
11 must be included on a written protocol determined by the delegating
12 physician and approved by the medical staff committee of the
13 facility or by direct verbal order of the delegating physician.
14 Physician assistants may not dispense drugs, but may request,
15 receive, and sign for professional samples and may distribute
16 professional samples to patients.
17 F. E. A physician assistant may perform health care services in
18 patient care settings as authorized by the delegating physician
19 practicing under a practice agreement may prescribe written and oral
20 prescriptions and orders. The physician assistant practicing under
21 a practice agreement may prescribe medical supplies, services, and
22 drugs, including controlled medications in Schedules II through V
23 pursuant to Section 2-312 of Title 63 of the Oklahoma Statutes,
24 written and oral prescriptions and orders only as delegated by the
Req. No. 12904 Page 12
1 dele gating physician, and prescriptions and orders for Schedule II
2 drugs written by such physician assistant shall be included on a
3 written protocol determined by the delegating physician. Physician
4 assistants practicing under a practice agreement may not dispense
5 drugs, but may request, receive, and sign for professional samples
6 and may distribute professional samples to patients. Provided that
7 a physician assistant practicing under a practice agreement may not
8 prescribe any controlled medications in a Schedule that the
9 delegating physician is not registered to prescribe.
10 G. F. Each physician assistant licensed under the Physician
11 Assistant Act shall keep his or her license available for inspection
12 at the primary place of business and shall, when engaged in
13 professional activities, identify himself or herself as a physician
14 assistant.
15 H. G. A physician assistant shall be bound by the provisions
16 contained in Sections 725.1 through 725.5 of Title 59 of the
17 Oklahoma Statutes this title.
18 SECTION 5. AMENDATORY 59 O.S. 2021, Section 519.11, as
19 amended by Section 1, Chapter 164, O.S.L. 2022 (59 O.S. Supp. 2024,
20 Section 519.11), is amended to read as follows:
21 Section 519.11 A. Nothing in the Physician Assistant Act shall
22 be construed to prevent or restrict the practice, services or
23 activities of any persons of other licensed professions or personnel
24 supervised by licensed professions in this state from performing
Req. No. 12904 Page 13
1 work incidental to the practice of their profession or occupation,
2 if that person does not represent himself or herself as a physician
3 assistant.
4 B. Nothing stated in the Physician Assistant Act shall prevent
5 any hospital from requiring the physician assistant or the
6 delegating physician to meet and maintain certain staff appointment
7 and credentialing qualifications for the privilege of practicing as,
8 or utilizing, a physician assistant in the hospital.
9 C. Nothing in the Physician Assistant Act shall be construed to
10 permit a physician assistant to practice medicine or prescribe drugs
11 and medical supplies in this state except when such actions are
12 performed under the supervision and at the direction of a physician
13 or physicians approved by the State Board of Medical Licensure and
14 Supervision.
15 D. Nothing herein shall be construed to require licensure under
16 the Physician Assistant Act of a physician assistant student
17 enrolled in a physician assistant educational program accredited by
18 the Accreditation Review Commission on Education for the Physician
19 Assistant.
20 E. D. Notwithstanding any other provision of law, no one who is
21 not a physician licensed to practice medicine in this state may
22 perform acts restricted to such physicians pursuant to the
23 provisions of Section 1-731 of Title 63 of the Oklahoma Statutes.
24 This paragraph subsection is inseverable.
Req. No. 12904 Page 14
1 F. E. Nothing in the Physician Assistant Act shall limit the
2 activities of a physician assistant in the performance of their
3 duties if the physician assistant is employed by or under contract
4 with the United States Department of Veterans Affairs or if the
5 physician assistant is employed by, under contract with, or
6 commissioned by one of the uniformed services; provided, the
7 physician assistant must be currently licensed in this state or any
8 other state or currently credentialed as a physician assistant by
9 the United States Department of Veterans Affairs or the applicable
10 uniformed service. Any physician assistant who is employed by or
11 under contract with the United States Department of Veterans Affairs
12 or is employed by, under contract with, or commissioned by one of
13 the uniformed services and practices outside of such employment,
14 contract, or commission shall be subject to the Physician Assistant
15 Act while practicing outside of such employment, contract, or
16 commission. As used in this subsection, "uniformed services" shall
17 have the same meaning as provided by Title 10 of the U.S. United
18 States Code.
19 SECTION 6. AMENDATORY 59 O.S. 2021, Section 521.2, is
20 amended to read as follows:
21 Section 521.2 A. Payment for services within the physician
22 assistant's scope of practice by a health insurance plan shall be
23 made when ordered or performed by the physician assistant, if the
24 same service would have been covered if ordered or performed by a
Req. No. 12904 Page 15
1 phys ician. An in-network A physician assistant shall be authorized
2 to bill for and receive direct payment for the medically necessary
3 services the physician assistant delivers.
4 B. To ensure accountability and transparency for patients,
5 payers and the health care system, an in-network a physician
6 assistant shall be identified as the rendering professional in the
7 billing and claims process when the physician assistant delivers
8 medical or surgical services to patients.
9 C. No insurance company or third-party payer shall impose a
10 practice, education, or collaboration requirement that is
11 inconsistent with or more restrictive than existing physician
12 assistant state laws or regulations.
13 SECTION 7. AMENDATORY 63 O.S. 2021, Section 1-317, as
14 last amended by Section 133, Chapter 452, O.S.L. 2024 (63 O.S. Supp.
15 2024, Section 1-317), is amended to read as follows:
16 Section 1-317. A. A death certificate for each death which
17 occurs in this state shall be filed with the State Department of
18 Health, within three (3) days after such death.
19 B. The funeral director shall personally sign the death
20 certificate and shall be responsible for filing the death
21 certificate. If the funeral director is not available, the person
22 acting as such who first assumes custody of a dead body in
23 accordance with Section 1158 of Title 21 of the Oklahoma Statutes
24 shall personally sign and file the death certificate. The personal
Req. No. 12904 Page 16
1 data shall be obtained from the next of kin or the best qualified
2 person or source available. The funeral director or person acting
3 as such shall notify the person providing the personal data that it
4 is a felony to knowingly provide false data or misrepresent any
5 person’s relationship to the decedent. The certificate shall be
6 completed as to personal data and delivered to the attending
7 physician or the medical examiner responsible for completing the
8 medical certification portion of the certificate of death within
9 twenty-four (24) hours after the death. No later than July 1, 2012,
10 the personal data, and no later than July 1, 2017, the medical
11 certificate portion, shall be entered into the prescribed electronic
12 system provided by the State Registrar of Vital Statistics and the
13 information submitted to the State Registrar of Vital Statistics.
14 The resultant certificate produced by the electronic system shall be
15 provided to the physician or medical examiner for medical
16 certification within twenty-four (24) hours after the death.
17 C. The medical certification shall be completed and signed
18 within forty-eight (48) hours after death by the physician,
19 physician assistant, or advanced practice registered nurse in charge
20 of the patient’s care for the illness or condition which resulted in
21 death, except when inquiry as to the cause of death is required by
22 Section 938 of this title. No later than July 1, 2017, the medical
23 certification portion of certificate data shall be entered into the
24 prescribed electronic system provided by the State Registrar of
Req. No. 12904 Page 17
1 Vita l Statistics and the information submitted to the State
2 Registrar of Vital Statistics.
3 D. In the event that the physician, physician assistant, or
4 advanced practice registered nurse in charge of the patient’s care
5 for the illness or condition which resulted in death is not in
6 attendance at the time of death, the medical certification shall be
7 completed and signed within forty-eight (48) hours after death by
8 the physician, physician assistant, or advanced practice registered
9 nurse in attendance at the time of death, except:
10 1. When the patient is under hospice care at the time of death,
11 the medical certification may be signed by the hospice’s medical
12 director; and
13 2. When inquiry as to the cause of death is required by Section
14 938 of this title.
15 Provided, that such certification, if signed by other than the
16 attending physician, physician assistant, or advanced practice
17 registered nurse, shall note on the face the name of the attending
18 physician, physician assistant, or advanced practice registered
19 nurse and that the information shown is only as reported.
20 E. A certifier completing cause of death on a certificate of
21 death who knows that a lethal drug, overdose or other means of
22 assisting suicide within the meaning of Sections 3141.2 through
23 3141.4 of this title caused or contributed to the death shall list
24 that means among the chain of events under cause of death or list it
Req. No. 12904 Page 18
1 in t he box that describes how the injury occurred. If such means is
2 in the chain of events under cause of death or in the box that
3 describes how the injury occurred, the certifier shall indicate
4 “suicide” as the manner of death.
5 F. The authority of a physician assistant subject to subsection
6 C of Section 519.6 of Title 59 of the Oklahoma Statutes to carry out
7 the functions described in this section shall be governed by the
8 practice agreement as provided by Section 519.6 of Title 59 of the
9 Oklahoma Statutes.
10 SECTION 8. AMENDATORY 63 O.S. 2021, Section 2-101, as
11 last amended by Section 1, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
12 2024, Section 2-101), is amended to read as follows:
13 Section 2-101. As used in the Uniform Controlled Dangerous
14 Substances Act:
15 1. “Acute pain” means pain, whether resulting from disease,
16 accidental trauma, intentional trauma, or other cause that the
17 practitioner reasonably expects to last only a short period of time.
18 Acute pain does not include chronic pain, pain being treated as part
19 of cancer care, hospice or other end-of-life care, or pain being
20 treated as part of palliative care;
21 2. “Administer” means the direct application of a controlled
22 dangerous substance, whether by injection, inhalation, ingestion or
23 any other means, to the body of a patient, animal or research
24 subject by:
Req. No. 12904 Page 19
1 a. a practitioner (or, in the presence of the
2 practitioner, by the authorized agent of the
3 practitioner), or
4 b. the patient or research subject at the direction and
5 in the presence of the practitioner;
6 3. “Agent” means a peace officer appointed by and who acts on
7 behalf of the Director of the Oklahoma State Bureau of Narcotics and
8 Dangerous Drugs Control or an authorized person who acts on behalf
9 of or at the direction of a person who manufactures, distributes,
10 dispenses, prescribes, administers or uses for scientific purposes
11 controlled dangerous substances but does not include a common or
12 contract carrier, public warehouser or employee thereof, or a person
13 required to register under the Uniform Controlled Dangerous
14 Substances Act;
15 4. “Anhydrous ammonia” means any substance that exhibits
16 cryogenic evaporative behavior and tests positive for ammonia;
17 5. “Board” means the Advisory Board to the Director of the
18 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
19 6. “Bureau” means the Oklahoma State Bureau of Narcotics and
20 Dangerous Drugs Control;
21 7. “Chronic pain” means pain that persists beyond the usual
22 course of an acute disease or healing of an injury. Chronic pain
23 may or may not be associated with an acute or chronic pathologic
24
Req. No. 12904 Page 20
1 proc ess that causes continuous or intermittent pain over months or
2 years;
3 8. “Coca leaves” includes cocaine and any compound,
4 manufacture, salt, derivative, mixture or preparation of coca
5 leaves, except derivatives of coca leaves which do not contain
6 cocaine or ecgonine;
7 9. “Commissioner” or “Director” means the Director of the
8 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
9 10. “Control” means to add, remove or change the placement of a
10 drug, substance or immediate precursor under the Uniform Controlled
11 Dangerous Substances Act;
12 11. “Controlled dangerous substance” means a drug, substance or
13 immediate precursor in Schedules I through V of the Uniform
14 Controlled Dangerous Substances Act or any drug, substance or
15 immediate precursor listed either temporarily or permanently as a
16 federally controlled substance. Any conflict between state and
17 federal law with regard to the particular schedule in which a
18 substance is listed shall be resolved in favor of state law;
19 12. “Counterfeit substance” means a controlled substance which,
20 or the container or labeling of which without authorization, bears
21 the trademark, trade name or other identifying marks, imprint,
22 number or device or any likeness thereof of a manufacturer,
23 distributor or dispenser other than the person who in fact
24 manufactured, distributed or dispensed the substance;
Req. No. 12904 Page 21
1 13. “Deliver” or “delivery” means the actual, constructive or
2 attempted transfer from one person to another of a controlled
3 dangerous substance or drug paraphernalia, whether or not there is
4 an agency relationship;
5 14. “Dispense” means to deliver a controlled dangerous
6 substance to an ultimate user or human research subject by or
7 pursuant to the lawful order of a practitioner, including the
8 prescribing, administering, packaging, labeling or compounding
9 necessary to prepare the substance for such distribution.
10 “Dispenser” is a practitioner who delivers a controlled dangerous
11 substance to an ultimate user or human research subject;
12 15. “Distribute” means to deliver other than by administering
13 or dispensing a controlled dangerous substance;
14 16. “Distributor” means a commercial entity engaged in the
15 distribution or reverse distribution of narcotics and dangerous
16 drugs and who complies with all regulations promulgated by the
17 federal Drug Enforcement Administration and the Oklahoma State
18 Bureau of Narcotics and Dangerous Drugs Control;
19 17. “Drug” means articles:
20 a. recognized in the official United States Pharmacopeia,
21 official Homeopathic Pharmacopoeia of the United
22 States, or official National Formulary, or any
23 supplement to any of them,
24
Req. No. 12904 Page 22
1 b. intended for use in the diagnosis, cure, mitigation,
2 treatment or prevention of disease in man or other
3 animals,
4 c. other than food, intended to affect the structure or
5 any function of the body of man or other animals, and
6 d. intended for use as a component of any article
7 specified in this paragraph;
8 provided, however, the term drug does not include devices or their
9 components, parts or accessories;
10 18. “Drug paraphernalia” means all equipment, products, and
11 materials of any kind which are used, intended for use, or fashioned
12 specifically for use in planting, propagating, cultivating, growing,
13 harvesting, manufacturing, compounding, converting, producing,
14 processing, preparing, testing, analyzing, packaging, repackaging,
15 storing, containing, concealing, injecting, ingesting, inhaling, or
16 otherwise introducing into the human body, a controlled dangerous
17 substance in violation of the Uniform Controlled Dangerous
18 Substances Act including, but not limited to:
19 a. kits used, intended for use, or fashioned specifically
20 for use in planting, propagating, cultivating,
21 growing, or harvesting of any species of plant which
22 is a controlled dangerous substance or from which a
23 controlled dangerous substance can be derived,
24
Req. No. 12904 Page 23
1 b. kits used, intended for use, or fashioned specifically
2 for use in manufacturing, compounding, converting,
3 producing, processing, or preparing controlled
4 dangerous substances,
5 c. isomerization devices used, intended for use, or
6 fashioned specifically for use in increasing the
7 potency of any species of plant which is a controlled
8 dangerous substance,
9 d. testing equipment used, intended for use, or fashioned
10 specifically for use in identifying or in analyzing
11 the strength, effectiveness, or purity of controlled
12 dangerous substances,
13 e. scales and balances used, intended for use, or
14 fashioned specifically for use in weighing or
15 measuring controlled dangerous substances,
16 f. diluents and adulterants, such as quinine
17 hydrochloride, mannitol, mannite, dextrose, and
18 lactose used, intended for use, or fashioned
19 specifically for use in cutting controlled dangerous
20 substances,
21 g. separation gins and sifters used, intended for use, or
22 fashioned specifically for use in removing twigs and
23 seeds from, or in otherwise cleaning or refining,
24 marijuana,
Req. No. 12904 Page 24
1 h. blenders, bowls, containers, spoons, and mixing
2 devices used, intended for use, or fashioned
3 specifically for use in compounding controlled
4 dangerous substances,
5 i. capsules, balloons, envelopes, and other containers
6 used, intended for use, or fashioned specifically for
7 use in packaging small quantities of controlled
8 dangerous substances,
9 j. containers and other objects used, intended for use,
10 or fashioned specifically for use in parenterally
11 injecting controlled dangerous substances into the
12 human body,
13 k. hypodermic syringes, needles, and other objects used,
14 intended for use, or fashioned specifically for use in
15 parenterally injecting controlled dangerous substances
16 into the human body, except as authorized by Section
17 2-1101 of this title,
18 l. objects used, intended for use, or fashioned
19 specifically for use in ingesting, inhaling, or
20 otherwise introducing marijuana, cocaine, hashish, or
21 hashish oil into the human body, such as:
22 (1) metal, wooden, acrylic, glass, stone, plastic, or
23 ceramic pipes with or without screens, permanent
24 screens, hashish heads, or punctured metal bowls,
Req. No. 12904 Page 25
1 (2) water pipes,
2 (3) carburetion tubes and devices,
3 (4) smoking and carburetion masks,
4 (5) roach clips, meaning objects used to hold burning
5 material, such as a marijuana cigarette, that has
6 become too small or too short to be held in the
7 hand,
8 (6) miniature cocaine spoons and cocaine vials,
9 (7) chamber pipes,
10 (8) carburetor pipes,
11 (9) electric pipes,
12 (10) air-driven pipes,
13 (11) chillums,
14 (12) bongs, or
15 (13) ice pipes or chillers,
16 m. all hidden or novelty pipes, and
17 n. any pipe that has a tobacco bowl or chamber of less
18 than one-half (1/2) inch in diameter in which there is
19 any detectable residue of any controlled dangerous
20 substance as defined in this section or any other
21 substances not legal for possession or use;
22 provided, however, the term drug paraphernalia shall not include
23 separation gins intended for use in preparing tea or spice, clamps
24 used for constructing electrical equipment, water pipes designed for
Req. No. 12904 Page 26
1 orna mentation in which no detectable amount of an illegal substance
2 is found or pipes designed and used solely for smoking tobacco,
3 traditional pipes of an American Indian tribal religious ceremony,
4 antique pipes that are thirty (30) years of age or older, or drug
5 testing strips possessed by a person for purposes of determining the
6 presence of fentanyl or a fentanyl-related compound;
7 19. “Drug-dependent person” means a person who is using a
8 controlled dangerous substance and who is in a state of psychic or
9 physical dependence, or both, arising from administration of that
10 controlled dangerous substance on a continuous basis. Drug
11 dependence is characterized by behavioral and other responses which
12 include a strong compulsion to take the substance on a continuous
13 basis in order to experience its psychic effects, or to avoid the
14 discomfort of its absence;
15 20. “Harm-reduction services” means programs established to:
16 a. reduce the spread of infectious diseases related to
17 injection drug use,
18 b. reduce drug dependency, overdose deaths, and
19 associated complications, and
20 c. increase safe recovery and disposal of used syringes
21 and sharp waste;
22 21. “Hazardous materials” means materials, whether solid,
23 liquid, or gas, which are toxic to human, animal, aquatic, or plant
24
Req. No. 12904 Page 27
1 life , and the disposal of such materials is controlled by state or
2 federal guidelines;
3 22. “Home care agency” means any sole proprietorship,
4 partnership, association, corporation, or other organization which
5 administers, offers, or provides home care services, for a fee or
6 pursuant to a contract for such services, to clients in their place
7 of residence;
8 23. “Home care services” means skilled or personal care
9 services provided to clients in their place of residence for a fee;
10 24. “Hospice” means a centrally administered, nonprofit or for-
11 profit, medically directed, nurse-coordinated program which provides
12 a continuum of home and inpatient care for the terminally ill
13 patient and the patient’s family. Such term shall also include a
14 centrally administered, nonprofit or for-profit, medically directed,
15 nurse-coordinated program if such program is licensed pursuant to
16 the provisions of the Uniform Controlled Dangerous Substances Act.
17 A hospice program offers palliative and supportive care to meet the
18 special needs arising out of the physical, emotional and spiritual
19 stresses which are experienced during the final stages of illness
20 and during dying and bereavement. This care is available twenty-
21 four (24) hours a day, seven (7) days a week, and is provided on the
22 basis of need, regardless of ability to pay. “Class A” Hospice
23 refers to Medicare-certified hospices. “Class B” refers to all
24 other providers of hospice services;
Req. No. 12904 Page 28
1 25. “Imitation controlled substance” means a substance that is
2 not a controlled dangerous substance, which by dosage unit
3 appearance, color, shape, size, markings or by representations made,
4 would lead a reasonable person to believe that the substance is a
5 controlled dangerous substance, or is a drug intended solely for
6 veterinary purposes that is not a controlled dangerous substance and
7 is being used outside of the scope of practice or normal course of
8 business, as defined by the State Board of Veterinary Medical
9 Examiners, or is a federal Food and Drug Administration-approved
10 drug that is not a controlled dangerous substance and is being used
11 outside the scope of approval for illicit purposes such as
12 adulterating or lacing other controlled dangerous substances. In
13 the event the appearance of the dosage unit or use is not reasonably
14 sufficient to establish that the substance is an imitation
15 controlled substance, the court or authority concerned should
16 consider, in addition to all other factors, the following factors:
17 a. statements made by an owner or by any other person in
18 control of the substance concerning the nature of the
19 substance, or its use or effect,
20 b. statements made to the recipient that the substance
21 may be resold for inordinate profit,
22 c. whether the substance is packaged in a manner normally
23 used for illicit controlled substances,
24
Req. No. 12904 Page 29
1 d. evasive tactics or actions utilized by the owner or
2 person in control of the substance to avoid detection
3 by law enforcement authorities,
4 e. prior convictions, if any, of an owner, or any other
5 person in control of the object, under state or
6 federal law related to controlled substances or fraud,
7 and
8 f. the proximity of the substances to controlled
9 dangerous substances;
10 26. “Immediate precursor” means a substance which the Director
11 has found to be and by regulation designates as being the principal
12 compound commonly used or produced primarily for use, and which is
13 an immediate chemical intermediary used, or likely to be used, in
14 the manufacture of a controlled dangerous substance, the control of
15 which is necessary to prevent, curtail or limit such manufacture;
16 27. “Initial prescription” means a prescription issued to a
17 patient who:
18 a. has never previously been issued a prescription for
19 the drug or its pharmaceutical equivalent in the past
20 year, or
21 b. requires a prescription for the drug or its
22 pharmaceutical equivalent due to a surgical procedure
23 or new acute event and has previously had a
24
Req. No. 12904 Page 30
1 prescription for the drug or its pharmaceutical
2 equivalent within the past year.
3 When determining whether a patient was previously issued a
4 prescription for a drug or its pharmaceutical equivalent, the
5 practitioner shall consult with the patient and review the medical
6 record and prescription monitoring information of the patient;
7 28. “Isomer” means the optical isomer, except as used in
8 subsections C and F of Section 2-204 of this title and paragraph 4
9 of subsection A of Section 2-206 of this title. As used in
10 subsections C and F of Section 2-204 of this title, isomer means the
11 optical, positional, or geometric isomer. As used in paragraph 4 of
12 subsection A of Section 2-206 of this title, the term isomer means
13 the optical or geometric isomer;
14 29. “Laboratory” means a laboratory approved by the Director as
15 proper to be entrusted with the custody of controlled dangerous
16 substances and the use of controlled dangerous substances for
17 scientific and medical purposes and for purposes of instruction;
18 30. “Manufacture” means the production, preparation,
19 propagation, compounding or processing of a controlled dangerous
20 substance, either directly or indirectly by extraction from
21 substances of natural or synthetic origin, or independently by means
22 of chemical synthesis or by a combination of extraction and chemical
23 synthesis. “Manufacturer” includes any person who packages,
24 repackages or labels any container of any controlled dangerous
Req. No. 12904 Page 31
1 subs tance, except practitioners who dispense or compound
2 prescription orders for delivery to the ultimate consumer;
3 31. “Marijuana” means all parts of the plant Cannabis sativa
4 L., whether growing or not; the seeds thereof; the resin extracted
5 from any part of such plant; and every compound, manufacture, salt,
6 derivative, mixture or preparation of such plant, its seeds or
7 resin, but shall not include:
8 a. the mature stalks of such plant or fiber produced from
9 such stalks,
10 b. oil or cake made from the seeds of such plant,
11 including cannabidiol derived from the seeds of the
12 marijuana plant,
13 c. any other compound, manufacture, salt, derivative,
14 mixture or preparation of such mature stalks (except
15 the resin extracted therefrom), including cannabidiol
16 derived from mature stalks, fiber, oil or cake,
17 d. the sterilized seed of such plant which is incapable
18 of germination,
19 e. for any person participating in a clinical trial to
20 administer cannabidiol for the treatment of severe
21 forms of epilepsy pursuant to Section 2-802 of this
22 title, a drug or substance approved by the federal
23 Food and Drug Administration for use by those
24 participants,
Req. No. 12904 Page 32
1 f. for any person or the parents, legal guardians or
2 caretakers of the person who have received a written
3 certification from a physician licensed in this state
4 that the person has been diagnosed by a physician as
5 having Lennox-Gastaut syndrome, Dravet syndrome, also
6 known as severe myoclonic epilepsy of infancy, or any
7 other severe form of epilepsy that is not adequately
8 treated by traditional medical therapies, spasticity
9 due to multiple sclerosis or due to paraplegia,
10 intractable nausea and vomiting, appetite stimulation
11 with chronic wasting diseases, the substance
12 cannabidiol, a nonpsychoactive cannabinoid, found in
13 the plant Cannabis sativa L. or any other preparation
14 thereof, that has a tetrahydrocannabinol concentration
15 not more than three-tenths of one percent (0.3%) and
16 that is delivered to the patient in the form of a
17 liquid,
18 g. any federal Food and Drug Administration-approved drug
19 or substance, or
20 h. industrial hemp, from the plant Cannabis sativa L. and
21 any part of such plant, whether growing or not, with a
22 delta-9 tetrahydrocannabinol concentration not more
23 than three-tenths of one percent (0.3%) on a dry-
24 weight basis which shall only be grown pursuant to the
Req. No. 12904 Page 33
1 Oklahoma Industrial Hemp Program and may be shipped
2 intrastate and interstate;
3 32. “Medical purpose” means an intention to utilize a
4 controlled dangerous substance for physical or mental treatment, for
5 diagnosis, or for the prevention of a disease condition not in
6 violation of any state or federal law and not for the purpose of
7 satisfying physiological or psychological dependence or other abuse;
8 33. “Mid-level practitioner” means an Advanced Practice
9 Registered Nurse as defined and within parameters specified in
10 Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
11 animal euthanasia technician as defined in Section 698.2 of Title 59
12 of the Oklahoma Statutes, or an animal control officer registered by
13 the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
14 under subsection B of Section 2-301 of this title within the
15 parameters of such officer’s duties under Sections 501 through 508
16 of Title 4 of the Oklahoma Statutes;
17 34. “Narcotic drug” means any of the following, whether
18 produced directly or indirectly by extraction from substances of
19 vegetable origin, or independently by means of chemical synthesis,
20 or by a combination of extraction and chemical synthesis:
21 a. opium, coca leaves and opiates,
22 b. a compound, manufacture, salt, derivative or
23 preparation of opium, coca leaves or opiates,
24
Req. No. 12904 Page 34
1 c. cocaine, its salts, optical and geometric isomers, and
2 salts of isomers,
3 d. ecgonine, its derivatives, their salts, isomers and
4 salts of isomers, and
5 e. a substance, and any compound, manufacture, salt,
6 derivative or preparation thereof, which is chemically
7 identical with any of the substances referred to in
8 subparagraphs a through d of this paragraph, except
9 that the words narcotic drug as used in Section 2-101
10 et seq. of this title shall not include decocainized
11 coca leaves or extracts of coca leaves, which extracts
12 do not contain cocaine or ecgonine;
13 35. “Opiate” or “opioid” means any Schedule II, III, IV or V
14 substance having an addiction-forming or addiction-sustaining
15 liability similar to morphine or being capable of conversion into a
16 drug having such addiction-forming or addiction-sustaining
17 liability. The terms do not include, unless specifically designated
18 as controlled under the Uniform Controlled Dangerous Substances Act,
19 the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
20 salts (dextromethorphan). The terms do include the racemic and
21 levorotatory forms;
22 36. “Opium poppy” means the plant of the species Papaver
23 somniferum L., except the seeds thereof;
24
Req. No. 12904 Page 35
1 37. “Palliative care” means a specialized medical service for
2 people of any age and at any stage of a serious illness or life-
3 altering medical event that focuses on navigating complex medical
4 decisions while providing patient autonomy and access to
5 information. Utilizing a holistic and interdisciplinary team
6 approach, palliative care addresses physical, intellectual,
7 emotional, social, and spiritual needs. Palliative care may be
8 provided in the inpatient, outpatient, or home care setting and
9 strives to improve quality of life for both the patient and the
10 family;
11 38. “Patient-provider agreement” means a written contract or
12 agreement that is executed between a practitioner and a patient
13 prior to the commencement of treatment for chronic pain using an
14 opioid drug as a means to:
15 a. explain the possible risk of development of physical
16 or psychological dependence in the patient and prevent
17 the possible development of addiction,
18 b. document the understanding of both the practitioner
19 and the patient regarding the patient-provider
20 agreement of the patient,
21 c. establish the rights of the patient in association
22 with treatment and the obligations of the patient in
23 relation to the responsible use, discontinuation of
24 use, and storage of opioid drugs, including any
Req. No. 12904 Page 36
1 restrictions on the refill of prescriptions or the
2 acceptance of opioid prescriptions from practitioners,
3 d. identify the specific medications and other modes of
4 treatment, including physical therapy or exercise,
5 relaxation, or psychological counseling, that are
6 included as a part of the patient-provider agreement,
7 e. specify the measures the practitioner may employ to
8 monitor the compliance of the patient including, but
9 not limited to, random specimen screens and pill
10 counts, and
11 f. delineate the process for terminating the agreement,
12 including the consequences if the practitioner has
13 reason to believe that the patient is not complying
14 with the terms of the agreement. Compliance with the
15 consent items described in this paragraph shall
16 constitute a valid, informed consent for opioid
17 therapy. The practitioner shall be held harmless from
18 civil litigation for failure to treat pain if the
19 event occurs because of nonadherence by the patient
20 with any of the provisions of the patient-provider
21 agreement;
22 39. “Peace officer” means a police officer, sheriff, deputy
23 sheriff, district attorney’s investigator, investigator from the
24 Office of the Attorney General, or any other person elected or
Req. No. 12904 Page 37
1 appo inted by law to enforce any of the criminal laws of this state
2 or of the United States;
3 40. “Person” means an individual, corporation, government or
4 governmental subdivision or agency, business trust, estate, trust,
5 partnership or association, or any other legal entity;
6 41. “Poppy straw” means all parts, except the seeds, of the
7 opium poppy, after mowing;
8 42. “Practitioner” means:
9 a. (1) a medical doctor or osteopathic physician,
10 (2) a dentist,
11 (3) a podiatrist,
12 (4) an optometrist,
13 (5) a veterinarian,
14 (6) a physician assistant or an Advanced Practice
15 Registered Nurse under the supervision of a
16 licensed medical doctor or osteopathic physician,
17 or a physician assistant,
18 (7) a scientific investigator, or
19 (8) any other person,
20 licensed, registered or otherwise permitted to
21 prescribe, distribute, dispense, conduct research with
22 respect to, use for scientific purposes or administer
23 a controlled dangerous substance in the course of
24 professional practice or research in this state, or
Req. No. 12904 Page 38
1 b. a pharmacy, hospital, laboratory or other institution
2 licensed, registered or otherwise permitted to
3 distribute, dispense, conduct research with respect
4 to, use for scientific purposes or administer a
5 controlled dangerous substance in the course of
6 professional practice or research in this state;
7 43. “Production” includes the manufacture, planting,
8 cultivation, growing or harvesting of a controlled dangerous
9 substance;
10 44. “Serious illness” means a medical illness or physical
11 injury or condition that substantially affects quality of life for
12 more than a short period of time. Serious illness includes, but is
13 not limited to, Alzheimer’s disease or related dementias, lung
14 disease, cancer, heart failure, renal failure, liver failure, or
15 chronic, unremitting, or intractable pain such as neuropathic pain;
16 45. “State” means the State of Oklahoma or any other state of
17 the United States;
18 46. “Straw person” or “straw party”, also known as a “front”,
19 means a third party who:
20 a. is put up in name only to take part in a transaction
21 or otherwise is a nominal party to a transaction with
22 no actual control,
23
24
Req. No. 12904 Page 39
1 b. acts on behalf of another person to obtain title to
2 property and executes documents and instruments the
3 principal may direct respecting property, or
4 c. purchases property for another for the purpose of
5 concealing the identity of the real purchaser or to
6 accomplish some purpose otherwise in violation of the
7 Oklahoma Statutes;
8 47. “Surgical procedure” means a procedure that is performed
9 for the purpose of structurally altering the human body by incision
10 or destruction of tissues as part of the practice of medicine. This
11 term includes the diagnostic or therapeutic treatment of conditions
12 or disease processes by use of instruments such as lasers,
13 ultrasound, ionizing, radiation, scalpels, probes, or needles that
14 cause localized alteration or transportation of live human tissue by
15 cutting, burning, vaporizing, freezing, suturing, probing, or
16 manipulating by closed reduction for major dislocations or
17 fractures, or otherwise altering by any mechanical, thermal, light-
18 based, electromagnetic, or chemical means;
19 48. a. “Synthetic controlled substance” means a substance:
20 (1) the chemical structure of which is substantially
21 similar to the chemical structure of a controlled
22 dangerous substance in Schedule I or II,
23 (2) which has a stimulant, depressant, or
24 hallucinogenic effect on the central nervous
Req. No. 12904 Page 40
1 system that is substantially similar to or
2 greater than the stimulant, depressant, or
3 hallucinogenic effect on the central nervous
4 system of a controlled dangerous substance in
5 Schedule I or II, or
6 (3) with respect to a particular person, which such
7 person represents or intends to have a stimulant,
8 depressant, or hallucinogenic effect on the
9 central nervous system that is substantially
10 similar to or greater than the stimulant,
11 depressant, or hallucinogenic effect on the
12 central nervous system of a controlled dangerous
13 substance in Schedule I or II.
14 b. The designation of gamma-butyrolactone or any other
15 chemical as a precursor, pursuant to Section 2-322 of
16 this title, does not preclude a finding pursuant to
17 subparagraph a of this paragraph that the chemical is
18 a synthetic controlled substance.
19 c. Synthetic controlled substance does not include:
20 (1) a controlled dangerous substance,
21 (2) any substance for which there is an approved new
22 drug application,
23 (3) with respect to a particular person any
24 substance, if an exemption is in effect for
Req. No. 12904 Page 41
1 investigational use, for that person under the
2 provisions of Section 505 of the Federal Food,
3 Drug, and Cosmetic Act, 21 U.S.C., Section 355,
4 to the extent conduct with respect to such
5 substance is pursuant to such exemption, or
6 (4) any substance to the extent not intended for
7 human consumption before such an exemption takes
8 effect with respect to that substance.
9 d. Prima facie evidence that a substance containing
10 salvia divinorum has been enhanced, concentrated, or
11 chemically or physically altered shall give rise to a
12 rebuttable presumption that the substance is a
13 synthetic controlled substance;
14 49. “Tetrahydrocannabinols” means all substances that have been
15 chemically synthesized to emulate the tetrahydrocannabinols of
16 marijuana, specifically including any tetrahydrocannabinols derived
17 from industrial hemp; and
18 50. “Ultimate user” means a person who lawfully possesses a
19 controlled dangerous substance for the person’s own use or for the
20 use of a member of the person’s household or for administration to
21 an animal owned by the person or by a member of the person’s
22 household.
23
24
Req. No. 12904 Page 42
1 SECTION 9. AMENDATORY 63 O.S. 2021, Section 2-312, as
2 amended by Section 2, Chapter 184, O.S.L. 2022 (63 O.S. Supp. 2024,
3 Section 2-312), is amended to read as follows:
4 Section 2-312. A. A physician, podiatrist, optometrist or a
5 dentist who has complied with the registration requirements of the
6 Uniform Controlled Dangerous Substances Act, in good faith and in
7 the course of such person's professional practice only, may
8 prescribe and administer controlled dangerous substances, or may
9 cause the same to be administered by medical or paramedical
10 personnel acting under the direction and supervision of the
11 physician, podiatrist, optometrist or dentist, and only may dispense
12 controlled dangerous substances pursuant to the provisions of
13 Sections 355.1 and 355.2 of Title 59 of the Oklahoma Statutes.
14 B. A veterinarian who has complied with the registration
15 requirements of the Uniform Controlled Dangerous Substances Act, in
16 good faith and in the course of the professional practice of the
17 veterinarian only, and not for use by a human being, may prescribe,
18 administer, and dispense controlled dangerous substances and may
19 cause them to be administered by an assistant or orderly under the
20 direction and supervision of the veterinarian.
21 C. An advanced practice nurse who is recognized to prescribe by
22 the Oklahoma Board of Nursing as an advanced registered nurse
23 practitioner, clinical nurse specialist or certified nurse-midwife,
24 who is subject to medical direction by a supervising physician,
Req. No. 12904 Page 43
1 purs uant to Section 567.3a of Title 59 of the Oklahoma Statutes, and
2 who has complied with the registration requirements of the Uniform
3 Controlled Dangerous Substances Act, in good faith and in the course
4 of professional practice only, may prescribe and administer Schedule
5 III, IV and V controlled dangerous substances.
6 D. An advanced practice nurse who is recognized to order,
7 select, obtain and administer drugs by the Oklahoma Board of Nursing
8 as a certified registered nurse anesthetist pursuant to Section
9 353.1b of Title 59 of the Oklahoma Statutes and who has complied
10 with the registration requirements of the Uniform Controlled
11 Dangerous Substances Act, in good faith and in the course of such
12 practitioner's professional practice only, may order, select, obtain
13 and administer Schedules II through V controlled dangerous
14 substances in a preanesthetic preparation or evaluation; anesthesia
15 induction, maintenance or emergence; or postanesthesia care setting
16 only. A certified registered nurse anesthetist may order, select,
17 obtain and administer such drugs only during the perioperative or
18 periobstetrical period.
19 E. A physician assistant who is recognized to prescribe by the
20 State Board of Medical Licensure and Supervision under the medical
21 direction of a supervising physician, pursuant to Section 519.6 of
22 Title 59 of the Oklahoma Statutes, and who has complied with the
23 registration requirements of the Uniform Controlled Dangerous
24 Substances Act, in good faith and in the course of professional
Req. No. 12904 Page 44
1 prac tice only, may prescribe and administer Schedule II through V
2 controlled dangerous substances subject to the restrictions in
3 Section 519.6 of Title 59 of the Oklahoma Statutes.
4 SECTION 10. REPEALER 59 O.S. 2021, Section 521.4, is
5 hereby repealed.
6 SECTION 11. It being immediately necessary for the preservation
7 of the public peace, health or safety, an emergency is hereby
8 declared to exist, by reason whereof this act shall take effect and
9 be in full force from and after its passage and approval.
10
11 60-1-12904 TJ 02/25/25
12
13
14
15
16
17
18
19
20
21
22
23
24
Req. No. 12904 Page 45
[DELETED:  P B]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P b r b]
[DELETED:  P r t]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P a t]
[DELETED:  P]
[DELETED:  P r]
[DELETED:  P i o i k]
[DELETED:  P k i t s d s]
[DELETED:  P b c c h o m]
[DELETED:  P w c s r m c c e a a]
[DELETED:  P r r i]
[DELETED:  P]
[DELETED:  P s s w]
[DELETED:  P e p t h r]
[DELETED:  P]
[DELETED:  P t o a t f]
[DELETED:  P f a i]
[DELETED:  P o a]
[DELETED:  P c e a]
[DELETED:  P e d e]
[DELETED:  P i s d]
[DELETED:  P ( a a a a a a a a]
[DELETED:  P a i]
[DELETED:  P a p a “ t w]
[DELETED:  P w T S a a w]
[DELETED:  P a P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P T 0]


================================================================================

Raw Text:
1 STATE OF OKLAHOMA
2 1st Session of the 60th Legislature (2025)
3 POLICY COMMITTEE
RECOMMENDATION
4 FOR
HOUSE BILL NO. 2584 By: Hilbert
5
6
7
8 POLICY COMMITTEE RECOMMENDATION
9 An Act relating to physician assistants; amending 59
O.S. 2021, Section 353.1a, which relates to the
10 Oklahoma Pharmacy Act; clarifying which prescriptions
for controlled dangerous substances pharmacists may
11 dispense; amending 59 O.S. 2021, Sections 519.2,
519.3, 519.6, 519.11, as amended by Section 1,
12 Chapter 164, O.S.L. 2022, and 521.2 (59 O.S. Supp.
2024, Section 519.11), which relate to the Physician
13 Assistant Act; modifying definitions; increasing the
number of Physician Assistant Committee members;
14 clarifying certain requirements for the chair;
increasing member requirements for a quorum; adding
15 provisions regarding postgraduate clinical practice;
clarifying filing requirements for practice
16 agreements; clarifying language regarding practicing
medicine, prescribing drugs, and using medical
17 supplies under a practice agreement; modifying
billing and payment authority; amending 63 O.S. 2021,
18 Section 1-317, as last amended by Section 133,
Chapter 452, O.S.L. 2024 (63 O.S. Supp. 2024, Section
19 1-317), which relates to the Oklahoma Public Health
Code; clarifying the authority of physician
20 assistants to carry out certain functions; amending
63 O.S. 2021, Sections 2-101, as last amended by
21 Section 1, Chapter 308, O.S.L. 2024, and 2-312, as
amended by Section 2, Chapter 184, O.S.L. 2022 (63
22 O.S. Supp. 2024, Sections 2-101 and 2-312), which
relate to the Uniform Controlled Dangerous Substances
23 Act; modifying definitions related to physician
assistants; clarifying which physician assistants may
24 prescribe and administer certain controlled
Req. No. 12904 Page 1

1 substances; repealing 59 O.S. 2021, Section 521.4,
which relates to physician supervision and practice
2 agreements; and declaring an emergency.
3
4
5 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
6 SECTION 1. AMENDATORY 59 O.S. 2021, Section 353.1a, is
7 amended to read as follows:
8 Section 353.1a A. Prescribing authority shall be allowed,
9 under the medical direction of a supervising physician, for an
10 advanced practice nurse recognized by the Oklahoma Board of Nursing
11 in one of the following categories: advanced registered nurse
12 practitioners, clinical nurse specialists, or certified nurse-
13 midwives. The advanced practice nurse may write or sign, or
14 transmit by word of mouth, telephone or other means of communication
15 an order for drugs or medical supplies that is intended to be
16 filled, compounded, or dispensed by a pharmacist. The supervising
17 physician and the advanced practice nurse shall be identified at the
18 time of origination of the prescription and the name of the advanced
19 practice nurse shall be printed on the prescription label.
20 B. Pharmacists may dispense prescriptions for non-controlled
21 prescription drugs authorized by an advanced practice nurse or
22 physician assistant, not located in Oklahoma, provided that they are
23 licensed in the state in which they are actively prescribing.
24
Req. No. 12904 Page 2

1 C. Pharmacists may only dispense prescriptions for controlled
2 dangerous substances prescribed by an:
3 1. An advanced practice nurse or physician assistant licensed
4 in the State of Oklahoma and supervised by an Oklahoma-licensed
5 practitioner; or
6 2. A physician assistant licensed in the State of Oklahoma and
7 supervised by an Oklahoma-licensed practitioner.
8 SECTION 2. AMENDATORY 59 O.S. 2021, Section 519.2, is
9 amended to read as follows:
10 Section 519.2 As used in the Physician Assistant Act:
11 1. "Board" means the State Board of Medical Licensure and
12 Supervision;
13 2. "Committee" means the Physician Assistant Committee;
14 3. "Practice of medicine" means services which require training
15 in the diagnosis, treatment and prevention of disease, including the
16 use and administration of drugs, and which are performed by
17 physician assistants so long as such services are within the
18 physician assistants' skill,. For a physician assistant required to
19 practice under supervision of a delegating physician, services form
20 a component of the physician's scope of practice, and are provided
21 with physician supervision, including authenticating by signature
22 any form that may be authenticated by the delegating physician's
23 signature with prior delegation by the physician;
24
Req. No. 12904 Page 3

1 4. "Patient care setting" means and includes, but is not
2 limited to, a physician's office, clinic, hospital, nursing home,
3 extended care facility, patient's home, ambulatory surgical center,
4 hospice facility or any other setting authorized by the delegating
5 physician;
6 5. "Physician assistant" means a health care professional,
7 qualified by academic and clinical education and licensed by the
8 State Board of Medical Licensure and Supervision, to practice
9 medicine with physician supervision as a physician assistant;
10 6. 5. "Delegating physician" means an individual holding a
11 license in good standing as a physician from the State Board of
12 Medical Licensure and Supervision or the State Board of Osteopathic
13 Examiners, who supervises one or more physician assistants and
14 delegates decision making pursuant to the practice agreement;
15 7. 6. "Supervision" means overseeing or delegating the
16 activities of the medical services rendered by a physician assistant
17 through a practice agreement between a medical doctor or osteopathic
18 delegating physician performing procedures or directly or indirectly
19 involved with the treatment of a patient, and the physician
20 assistant working jointly toward a common goal of providing
21 services. Delegation shall be defined by the practice agreement.
22 The physical presence of the delegating physician is not required as
23 long as the delegating physician and physician assistant are or can
24 be easily in contact with each other by telecommunication. At all
Req. No. 12904 Page 4

1 time s a physician assistant required to practice under supervision
2 shall be considered an agent of the delegating physician;
3 8. 7. "Telecommunication" means the use of electronic
4 technologies to transmit words, sounds or images for interpersonal
5 communication, clinical care (telemedicine) and review of electronic
6 health records; and
7 9. 8. "Practice agreement" means a written agreement between a
8 physician assistant and the a delegating physician concerning the
9 scope of practice of the physician assistant to only be determined
10 by the delegating physician and the physician assistant based on the
11 education, training, skills and experience of the physician
12 assistant. The agreement shall involve the joint formulation,
13 discussion and agreement on the methods of supervision and
14 collaboration for diagnosis, consultation and treatment of medical
15 conditions and shall include the scope of and any limitations on
16 prescribing. A practice agreement is required for a physician
17 assistant as described in subsection C of Section 519.6 of this
18 title.
19 SECTION 3. AMENDATORY 59 O.S. 2021, Section 519.3, is
20 amended to read as follows:
21 Section 519.3 A. There is hereby created the Physician
22 Assistant Committee, which shall be composed of seven (7) nine (9)
23 members. Three Five members of the Committee shall be physician
24 assistants appointed by the State Board of Medical Licensure and
Req. No. 12904 Page 5

1 Supe rvision from a list of qualified individuals submitted by the
2 Oklahoma Academy of Physician Assistants. One member shall be a
3 physician appointed by the Board from its membership. One member
4 shall be a physician appointed by the Board from a list of qualified
5 individuals submitted by the Oklahoma State Medical Association and
6 who is not a member of the Board. One member shall be a physician
7 appointed by the State Board of Osteopathic Examiners from its
8 membership. One member shall be a physician appointed by the State
9 Board of Osteopathic Examiners from a list of qualified individuals
10 submitted by the Oklahoma Osteopathic Association and who is not a
11 member of said board.
12 B. The term of office for each member of the Committee shall be
13 five (5) years.
14 C. The Committee shall meet at least quarterly. At the initial
15 meeting of each calendar year, the Committee members shall elect a
16 chair from the physician assistant members. The chair or his or her
17 designee shall represent the Committee at all meetings of the Board.
18 Four Five members shall constitute a quorum for the purpose of
19 conducting official business of the Committee.
20 D. The State Board of Medical Licensure and Supervision is
21 hereby granted the power and authority to promulgate rules, which
22 are in accordance with the provisions of Section 519.1 et seq. of
23 this title, governing the requirements for licensure as a physician
24 assistant, as well as to establish standards for training, approve
Req. No. 12904 Page 6

1 inst itutions for training, and regulate the standards of practice of
2 a physician assistant after licensure, including the power of
3 revocation of a license.
4 E. The State Board of Medical Licensure and Supervision is
5 hereby granted the power and authority to investigate all
6 complaints, hold hearings, subpoena witnesses and initiate
7 prosecution concerning violations of Section 519.1 et seq. of this
8 title. When such complaints involve physicians licensed by the
9 State Board of Osteopathic Examiners, the State Board of Osteopathic
10 Examiners shall be officially notified of such complaints.
11 F. 1. The Committee shall advise the Board on all matters
12 pertaining to the practice of physician assistants.
13 2. The Committee shall review and make recommendations to the
14 Board on all applications for licensure as a physician assistant and
15 all applications to practice which shall be approved by the Board.
16 When considering applicants for licensure, to establish standards of
17 training or approve institutions for training, the Committee shall
18 include the Director, or designee, of all Physician Assistant
19 educational programs conducted by institutions of higher education
20 in the state as members.
21 3. The Committee shall assist and advise the Board in all
22 hearings involving physician assistants who are deemed to be in
23 violation of Section 519.1 et seq. of this title or the rules of the
24 Board.
Req. No. 12904 Page 7

1 SECTION 4. AMENDATORY 59 O.S. 2021, Section 519.6, is
2 amended to read as follows:
3 Section 519.6 A. No health care services may be performed by a
4 physician assistant unless a current license is on file with and
5 approved by the State Board of Medical Licensure and Supervision.
6 B. A physician assistant with six thousand two hundred forty
7 (6,240) or more hours of postgraduate clinical practice experience
8 who has reported those hours to the Board shall not be required to
9 practice under the supervision of a delegating physician.
10 1. A physician assistant may report the completion of
11 postgraduate clinical practice experience to the Board at any time
12 after completion of at least six thousand two hundred forty (6,240)
13 such hours.
14 2. Hours earned prior to the enactment of this subsection shall
15 be counted towards the six thousand two hundred forty (6,240) hours.
16 3. The Board shall maintain, make available, and keep updated,
17 on the Internet website of the Board, a list of physician assistants
18 who have reported completion of six thousand two hundred forty
19 (6,240) or more postgraduate clinical practice experience hours.
20 4. The Board shall, within ninety (90) days of enactment,
21 prescribe a form for reporting postgraduate clinical practice
22 experience by a physician assistant. The Board shall make available
23 and keep updated on the Internet website of the Board the prescribed
24 form. This reporting form may be filed electronically. The Board
Req. No. 12904 Page 8

1 shal l not charge a fee for reporting hours or filing of the
2 prescribed form.
3 5. Nothing in this subsection shall prohibit a physician
4 assistant from maintaining a practice agreement; however, such an
5 agreement is not required for a physician assistant with the
6 reported six thousand two hundred forty (6,240) hours of
7 postgraduate clinical practice experience, provided any practice
8 agreements are subject to the requirements of paragraphs 1, 2, 3,
9 and 4 of subsection C of this section.
10 6. Nothing in this subsection shall restrict the ability of the
11 Board to require supervision as a part of disciplinary action
12 against the license of a physician assistant.
13 C. A physician assistant with less than six thousand two
14 hundred forty (6,240) hours of postgraduate clinical practice
15 experience or who has completed six thousand two hundred forty
16 (6,240) hours but has not reported those hours to the Board shall
17 practice under the supervision of a delegating physician with the
18 following requirements:
19 1. All practice agreements and any amendments shall be filed
20 with the State Board of Medical Licensure and Supervision within ten
21 (10) business days of being executed. Practice agreements may be
22 filed electronically. The State Board of Medical Licensure and
23 Supervision shall not charge a fee for filing practice agreements or
24 amendments of to practice agreements.;
Req. No. 12904 Page 9

1 B. 2. A physician assistant may have practice agreements with
2 multiple allopathic or osteopathic physicians. Each physician shall
3 be in good standing with the State Board of Medical Licensure and
4 Supervision or the State Board of Osteopathic Examiners.;
5 C. 3. The delegating physician need not be physically present
6 nor be specifically consulted before each delegated patient care
7 service is performed by a physician assistant, so long as the
8 delegating physician and physician assistant are or can be easily in
9 contact with one another by means of telecommunication. In all
10 patient care settings, the The delegating physician shall provide
11 appropriate methods of participating in health care services
12 provided by the physician assistant including:
13 a. being responsible for the formulation or approval of
14 all orders and protocols, whether standing orders,
15 direct orders or any other orders or protocols, which
16 direct the delivery of health care services provided
17 by a physician assistant, and periodically reviewing
18 such orders and protocols,
19 b. regularly reviewing the health care services provided
20 by the physician assistant and any problems or
21 complications encountered,
22 c. being available physically or through telemedicine or
23 direct telecommunications for consultation, assistance
24 with medical emergencies or patient referral,
Req. No. 12904 Page 10

1 d. reviewing a sample of outpatient medical records.
2 Such reviews shall take place at a site agreed upon
3 between the delegating physician and physician
4 assistant in the practice agreement which may also
5 occur using electronic or virtual conferencing, and
6 e. that it remains clear that the physician assistant is
7 an agent of the delegating physician; but, in no event
8 shall the delegating physician be an employee of the
9 physician assistant.;
10 D. 4. In patients with newly diagnosed complex illnesses, the
11 physician assistant shall contact the delegating physician within
12 forty-eight (48) hours of the physician assistant's initial
13 examination or treatment and schedule the patient for appropriate
14 evaluation by the delegating physician as directed by the physician.
15 The delegating physician shall determine which conditions qualify as
16 complex illnesses based on the clinical setting and the skill and
17 experience of the physician assistant.
18 E. 1. D. A physician assistant under the direction of a
19 delegating physician not practicing under a practice agreement may
20 prescribe written and oral prescriptions and orders. The physician
21 assistant not practicing under a practice agreement may prescribe
22 medical supplies, services, and drugs, including controlled
23 medications in Schedules II III through V pursuant to Section 2-312
24 of Title 63 of the Oklahoma Statutes, and medical supplies and
Req. No. 12904 Page 11

1 serv ices as delegated by the delegating physician and as approved by
2 the State Board of Medical Licensure and Supervision after
3 consultation with the State Board of Pharmacy on the Physician
4 Assistant Drug Formulary. Physician assistants not practicing under
5 a practice agreement may not dispense drugs, but may request,
6 receive, and sign for professional samples and may distribute
7 professional samples to patients.
8 2. A physician assistant may write an order for a Schedule II
9 drug for immediate or ongoing administration on site. Prescriptions
10 and orders for Schedule II drugs written by a physician assistant
11 must be included on a written protocol determined by the delegating
12 physician and approved by the medical staff committee of the
13 facility or by direct verbal order of the delegating physician.
14 Physician assistants may not dispense drugs, but may request,
15 receive, and sign for professional samples and may distribute
16 professional samples to patients.
17 F. E. A physician assistant may perform health care services in
18 patient care settings as authorized by the delegating physician
19 practicing under a practice agreement may prescribe written and oral
20 prescriptions and orders. The physician assistant practicing under
21 a practice agreement may prescribe medical supplies, services, and
22 drugs, including controlled medications in Schedules II through V
23 pursuant to Section 2-312 of Title 63 of the Oklahoma Statutes,
24 written and oral prescriptions and orders only as delegated by the
Req. No. 12904 Page 12

1 dele gating physician, and prescriptions and orders for Schedule II
2 drugs written by such physician assistant shall be included on a
3 written protocol determined by the delegating physician. Physician
4 assistants practicing under a practice agreement may not dispense
5 drugs, but may request, receive, and sign for professional samples
6 and may distribute professional samples to patients. Provided that
7 a physician assistant practicing under a practice agreement may not
8 prescribe any controlled medications in a Schedule that the
9 delegating physician is not registered to prescribe.
10 G. F. Each physician assistant licensed under the Physician
11 Assistant Act shall keep his or her license available for inspection
12 at the primary place of business and shall, when engaged in
13 professional activities, identify himself or herself as a physician
14 assistant.
15 H. G. A physician assistant shall be bound by the provisions
16 contained in Sections 725.1 through 725.5 of Title 59 of the
17 Oklahoma Statutes this title.
18 SECTION 5. AMENDATORY 59 O.S. 2021, Section 519.11, as
19 amended by Section 1, Chapter 164, O.S.L. 2022 (59 O.S. Supp. 2024,
20 Section 519.11), is amended to read as follows:
21 Section 519.11 A. Nothing in the Physician Assistant Act shall
22 be construed to prevent or restrict the practice, services or
23 activities of any persons of other licensed professions or personnel
24 supervised by licensed professions in this state from performing
Req. No. 12904 Page 13

1 work incidental to the practice of their profession or occupation,
2 if that person does not represent himself or herself as a physician
3 assistant.
4 B. Nothing stated in the Physician Assistant Act shall prevent
5 any hospital from requiring the physician assistant or the
6 delegating physician to meet and maintain certain staff appointment
7 and credentialing qualifications for the privilege of practicing as,
8 or utilizing, a physician assistant in the hospital.
9 C. Nothing in the Physician Assistant Act shall be construed to
10 permit a physician assistant to practice medicine or prescribe drugs
11 and medical supplies in this state except when such actions are
12 performed under the supervision and at the direction of a physician
13 or physicians approved by the State Board of Medical Licensure and
14 Supervision.
15 D. Nothing herein shall be construed to require licensure under
16 the Physician Assistant Act of a physician assistant student
17 enrolled in a physician assistant educational program accredited by
18 the Accreditation Review Commission on Education for the Physician
19 Assistant.
20 E. D. Notwithstanding any other provision of law, no one who is
21 not a physician licensed to practice medicine in this state may
22 perform acts restricted to such physicians pursuant to the
23 provisions of Section 1-731 of Title 63 of the Oklahoma Statutes.
24 This paragraph subsection is inseverable.
Req. No. 12904 Page 14

1 F. E. Nothing in the Physician Assistant Act shall limit the
2 activities of a physician assistant in the performance of their
3 duties if the physician assistant is employed by or under contract
4 with the United States Department of Veterans Affairs or if the
5 physician assistant is employed by, under contract with, or
6 commissioned by one of the uniformed services; provided, the
7 physician assistant must be currently licensed in this state or any
8 other state or currently credentialed as a physician assistant by
9 the United States Department of Veterans Affairs or the applicable
10 uniformed service. Any physician assistant who is employed by or
11 under contract with the United States Department of Veterans Affairs
12 or is employed by, under contract with, or commissioned by one of
13 the uniformed services and practices outside of such employment,
14 contract, or commission shall be subject to the Physician Assistant
15 Act while practicing outside of such employment, contract, or
16 commission. As used in this subsection, "uniformed services" shall
17 have the same meaning as provided by Title 10 of the U.S. United
18 States Code.
19 SECTION 6. AMENDATORY 59 O.S. 2021, Section 521.2, is
20 amended to read as follows:
21 Section 521.2 A. Payment for services within the physician
22 assistant's scope of practice by a health insurance plan shall be
23 made when ordered or performed by the physician assistant, if the
24 same service would have been covered if ordered or performed by a
Req. No. 12904 Page 15

1 phys ician. An in-network A physician assistant shall be authorized
2 to bill for and receive direct payment for the medically necessary
3 services the physician assistant delivers.
4 B. To ensure accountability and transparency for patients,
5 payers and the health care system, an in-network a physician
6 assistant shall be identified as the rendering professional in the
7 billing and claims process when the physician assistant delivers
8 medical or surgical services to patients.
9 C. No insurance company or third-party payer shall impose a
10 practice, education, or collaboration requirement that is
11 inconsistent with or more restrictive than existing physician
12 assistant state laws or regulations.
13 SECTION 7. AMENDATORY 63 O.S. 2021, Section 1-317, as
14 last amended by Section 133, Chapter 452, O.S.L. 2024 (63 O.S. Supp.
15 2024, Section 1-317), is amended to read as follows:
16 Section 1-317. A. A death certificate for each death which
17 occurs in this state shall be filed with the State Department of
18 Health, within three (3) days after such death.
19 B. The funeral director shall personally sign the death
20 certificate and shall be responsible for filing the death
21 certificate. If the funeral director is not available, the person
22 acting as such who first assumes custody of a dead body in
23 accordance with Section 1158 of Title 21 of the Oklahoma Statutes
24 shall personally sign and file the death certificate. The personal
Req. No. 12904 Page 16

1 data shall be obtained from the next of kin or the best qualified
2 person or source available. The funeral director or person acting
3 as such shall notify the person providing the personal data that it
4 is a felony to knowingly provide false data or misrepresent any
5 person’s relationship to the decedent. The certificate shall be
6 completed as to personal data and delivered to the attending
7 physician or the medical examiner responsible for completing the
8 medical certification portion of the certificate of death within
9 twenty-four (24) hours after the death. No later than July 1, 2012,
10 the personal data, and no later than July 1, 2017, the medical
11 certificate portion, shall be entered into the prescribed electronic
12 system provided by the State Registrar of Vital Statistics and the
13 information submitted to the State Registrar of Vital Statistics.
14 The resultant certificate produced by the electronic system shall be
15 provided to the physician or medical examiner for medical
16 certification within twenty-four (24) hours after the death.
17 C. The medical certification shall be completed and signed
18 within forty-eight (48) hours after death by the physician,
19 physician assistant, or advanced practice registered nurse in charge
20 of the patient’s care for the illness or condition which resulted in
21 death, except when inquiry as to the cause of death is required by
22 Section 938 of this title. No later than July 1, 2017, the medical
23 certification portion of certificate data shall be entered into the
24 prescribed electronic system provided by the State Registrar of
Req. No. 12904 Page 17

1 Vita l Statistics and the information submitted to the State
2 Registrar of Vital Statistics.
3 D. In the event that the physician, physician assistant, or
4 advanced practice registered nurse in charge of the patient’s care
5 for the illness or condition which resulted in death is not in
6 attendance at the time of death, the medical certification shall be
7 completed and signed within forty-eight (48) hours after death by
8 the physician, physician assistant, or advanced practice registered
9 nurse in attendance at the time of death, except:
10 1. When the patient is under hospice care at the time of death,
11 the medical certification may be signed by the hospice’s medical
12 director; and
13 2. When inquiry as to the cause of death is required by Section
14 938 of this title.
15 Provided, that such certification, if signed by other than the
16 attending physician, physician assistant, or advanced practice
17 registered nurse, shall note on the face the name of the attending
18 physician, physician assistant, or advanced practice registered
19 nurse and that the information shown is only as reported.
20 E. A certifier completing cause of death on a certificate of
21 death who knows that a lethal drug, overdose or other means of
22 assisting suicide within the meaning of Sections 3141.2 through
23 3141.4 of this title caused or contributed to the death shall list
24 that means among the chain of events under cause of death or list it
Req. No. 12904 Page 18

1 in t he box that describes how the injury occurred. If such means is
2 in the chain of events under cause of death or in the box that
3 describes how the injury occurred, the certifier shall indicate
4 “suicide” as the manner of death.
5 F. The authority of a physician assistant subject to subsection
6 C of Section 519.6 of Title 59 of the Oklahoma Statutes to carry out
7 the functions described in this section shall be governed by the
8 practice agreement as provided by Section 519.6 of Title 59 of the
9 Oklahoma Statutes.
10 SECTION 8. AMENDATORY 63 O.S. 2021, Section 2-101, as
11 last amended by Section 1, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
12 2024, Section 2-101), is amended to read as follows:
13 Section 2-101. As used in the Uniform Controlled Dangerous
14 Substances Act:
15 1. “Acute pain” means pain, whether resulting from disease,
16 accidental trauma, intentional trauma, or other cause that the
17 practitioner reasonably expects to last only a short period of time.
18 Acute pain does not include chronic pain, pain being treated as part
19 of cancer care, hospice or other end-of-life care, or pain being
20 treated as part of palliative care;
21 2. “Administer” means the direct application of a controlled
22 dangerous substance, whether by injection, inhalation, ingestion or
23 any other means, to the body of a patient, animal or research
24 subject by:
Req. No. 12904 Page 19

1 a. a practitioner (or, in the presence of the
2 practitioner, by the authorized agent of the
3 practitioner), or
4 b. the patient or research subject at the direction and
5 in the presence of the practitioner;
6 3. “Agent” means a peace officer appointed by and who acts on
7 behalf of the Director of the Oklahoma State Bureau of Narcotics and
8 Dangerous Drugs Control or an authorized person who acts on behalf
9 of or at the direction of a person who manufactures, distributes,
10 dispenses, prescribes, administers or uses for scientific purposes
11 controlled dangerous substances but does not include a common or
12 contract carrier, public warehouser or employee thereof, or a person
13 required to register under the Uniform Controlled Dangerous
14 Substances Act;
15 4. “Anhydrous ammonia” means any substance that exhibits
16 cryogenic evaporative behavior and tests positive for ammonia;
17 5. “Board” means the Advisory Board to the Director of the
18 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
19 6. “Bureau” means the Oklahoma State Bureau of Narcotics and
20 Dangerous Drugs Control;
21 7. “Chronic pain” means pain that persists beyond the usual
22 course of an acute disease or healing of an injury. Chronic pain
23 may or may not be associated with an acute or chronic pathologic
24
Req. No. 12904 Page 20

1 proc ess that causes continuous or intermittent pain over months or
2 years;
3 8. “Coca leaves” includes cocaine and any compound,
4 manufacture, salt, derivative, mixture or preparation of coca
5 leaves, except derivatives of coca leaves which do not contain
6 cocaine or ecgonine;
7 9. “Commissioner” or “Director” means the Director of the
8 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
9 10. “Control” means to add, remove or change the placement of a
10 drug, substance or immediate precursor under the Uniform Controlled
11 Dangerous Substances Act;
12 11. “Controlled dangerous substance” means a drug, substance or
13 immediate precursor in Schedules I through V of the Uniform
14 Controlled Dangerous Substances Act or any drug, substance or
15 immediate precursor listed either temporarily or permanently as a
16 federally controlled substance. Any conflict between state and
17 federal law with regard to the particular schedule in which a
18 substance is listed shall be resolved in favor of state law;
19 12. “Counterfeit substance” means a controlled substance which,
20 or the container or labeling of which without authorization, bears
21 the trademark, trade name or other identifying marks, imprint,
22 number or device or any likeness thereof of a manufacturer,
23 distributor or dispenser other than the person who in fact
24 manufactured, distributed or dispensed the substance;
Req. No. 12904 Page 21

1 13. “Deliver” or “delivery” means the actual, constructive or
2 attempted transfer from one person to another of a controlled
3 dangerous substance or drug paraphernalia, whether or not there is
4 an agency relationship;
5 14. “Dispense” means to deliver a controlled dangerous
6 substance to an ultimate user or human research subject by or
7 pursuant to the lawful order of a practitioner, including the
8 prescribing, administering, packaging, labeling or compounding
9 necessary to prepare the substance for such distribution.
10 “Dispenser” is a practitioner who delivers a controlled dangerous
11 substance to an ultimate user or human research subject;
12 15. “Distribute” means to deliver other than by administering
13 or dispensing a controlled dangerous substance;
14 16. “Distributor” means a commercial entity engaged in the
15 distribution or reverse distribution of narcotics and dangerous
16 drugs and who complies with all regulations promulgated by the
17 federal Drug Enforcement Administration and the Oklahoma State
18 Bureau of Narcotics and Dangerous Drugs Control;
19 17. “Drug” means articles:
20 a. recognized in the official United States Pharmacopeia,
21 official Homeopathic Pharmacopoeia of the United
22 States, or official National Formulary, or any
23 supplement to any of them,
24
Req. No. 12904 Page 22

1 b. intended for use in the diagnosis, cure, mitigation,
2 treatment or prevention of disease in man or other
3 animals,
4 c. other than food, intended to affect the structure or
5 any function of the body of man or other animals, and
6 d. intended for use as a component of any article
7 specified in this paragraph;
8 provided, however, the term drug does not include devices or their
9 components, parts or accessories;
10 18. “Drug paraphernalia” means all equipment, products, and
11 materials of any kind which are used, intended for use, or fashioned
12 specifically for use in planting, propagating, cultivating, growing,
13 harvesting, manufacturing, compounding, converting, producing,
14 processing, preparing, testing, analyzing, packaging, repackaging,
15 storing, containing, concealing, injecting, ingesting, inhaling, or
16 otherwise introducing into the human body, a controlled dangerous
17 substance in violation of the Uniform Controlled Dangerous
18 Substances Act including, but not limited to:
19 a. kits used, intended for use, or fashioned specifically
20 for use in planting, propagating, cultivating,
21 growing, or harvesting of any species of plant which
22 is a controlled dangerous substance or from which a
23 controlled dangerous substance can be derived,
24
Req. No. 12904 Page 23

1 b. kits used, intended for use, or fashioned specifically
2 for use in manufacturing, compounding, converting,
3 producing, processing, or preparing controlled
4 dangerous substances,
5 c. isomerization devices used, intended for use, or
6 fashioned specifically for use in increasing the
7 potency of any species of plant which is a controlled
8 dangerous substance,
9 d. testing equipment used, intended for use, or fashioned
10 specifically for use in identifying or in analyzing
11 the strength, effectiveness, or purity of controlled
12 dangerous substances,
13 e. scales and balances used, intended for use, or
14 fashioned specifically for use in weighing or
15 measuring controlled dangerous substances,
16 f. diluents and adulterants, such as quinine
17 hydrochloride, mannitol, mannite, dextrose, and
18 lactose used, intended for use, or fashioned
19 specifically for use in cutting controlled dangerous
20 substances,
21 g. separation gins and sifters used, intended for use, or
22 fashioned specifically for use in removing twigs and
23 seeds from, or in otherwise cleaning or refining,
24 marijuana,
Req. No. 12904 Page 24

1 h. blenders, bowls, containers, spoons, and mixing
2 devices used, intended for use, or fashioned
3 specifically for use in compounding controlled
4 dangerous substances,
5 i. capsules, balloons, envelopes, and other containers
6 used, intended for use, or fashioned specifically for
7 use in packaging small quantities of controlled
8 dangerous substances,
9 j. containers and other objects used, intended for use,
10 or fashioned specifically for use in parenterally
11 injecting controlled dangerous substances into the
12 human body,
13 k. hypodermic syringes, needles, and other objects used,
14 intended for use, or fashioned specifically for use in
15 parenterally injecting controlled dangerous substances
16 into the human body, except as authorized by Section
17 2-1101 of this title,
18 l. objects used, intended for use, or fashioned
19 specifically for use in ingesting, inhaling, or
20 otherwise introducing marijuana, cocaine, hashish, or
21 hashish oil into the human body, such as:
22 (1) metal, wooden, acrylic, glass, stone, plastic, or
23 ceramic pipes with or without screens, permanent
24 screens, hashish heads, or punctured metal bowls,
Req. No. 12904 Page 25

1 (2) water pipes,
2 (3) carburetion tubes and devices,
3 (4) smoking and carburetion masks,
4 (5) roach clips, meaning objects used to hold burning
5 material, such as a marijuana cigarette, that has
6 become too small or too short to be held in the
7 hand,
8 (6) miniature cocaine spoons and cocaine vials,
9 (7) chamber pipes,
10 (8) carburetor pipes,
11 (9) electric pipes,
12 (10) air-driven pipes,
13 (11) chillums,
14 (12) bongs, or
15 (13) ice pipes or chillers,
16 m. all hidden or novelty pipes, and
17 n. any pipe that has a tobacco bowl or chamber of less
18 than one-half (1/2) inch in diameter in which there is
19 any detectable residue of any controlled dangerous
20 substance as defined in this section or any other
21 substances not legal for possession or use;
22 provided, however, the term drug paraphernalia shall not include
23 separation gins intended for use in preparing tea or spice, clamps
24 used for constructing electrical equipment, water pipes designed for
Req. No. 12904 Page 26

1 orna mentation in which no detectable amount of an illegal substance
2 is found or pipes designed and used solely for smoking tobacco,
3 traditional pipes of an American Indian tribal religious ceremony,
4 antique pipes that are thirty (30) years of age or older, or drug
5 testing strips possessed by a person for purposes of determining the
6 presence of fentanyl or a fentanyl-related compound;
7 19. “Drug-dependent person” means a person who is using a
8 controlled dangerous substance and who is in a state of psychic or
9 physical dependence, or both, arising from administration of that
10 controlled dangerous substance on a continuous basis. Drug
11 dependence is characterized by behavioral and other responses which
12 include a strong compulsion to take the substance on a continuous
13 basis in order to experience its psychic effects, or to avoid the
14 discomfort of its absence;
15 20. “Harm-reduction services” means programs established to:
16 a. reduce the spread of infectious diseases related to
17 injection drug use,
18 b. reduce drug dependency, overdose deaths, and
19 associated complications, and
20 c. increase safe recovery and disposal of used syringes
21 and sharp waste;
22 21. “Hazardous materials” means materials, whether solid,
23 liquid, or gas, which are toxic to human, animal, aquatic, or plant
24
Req. No. 12904 Page 27

1 life , and the disposal of such materials is controlled by state or
2 federal guidelines;
3 22. “Home care agency” means any sole proprietorship,
4 partnership, association, corporation, or other organization which
5 administers, offers, or provides home care services, for a fee or
6 pursuant to a contract for such services, to clients in their place
7 of residence;
8 23. “Home care services” means skilled or personal care
9 services provided to clients in their place of residence for a fee;
10 24. “Hospice” means a centrally administered, nonprofit or for-
11 profit, medically directed, nurse-coordinated program which provides
12 a continuum of home and inpatient care for the terminally ill
13 patient and the patient’s family. Such term shall also include a
14 centrally administered, nonprofit or for-profit, medically directed,
15 nurse-coordinated program if such program is licensed pursuant to
16 the provisions of the Uniform Controlled Dangerous Substances Act.
17 A hospice program offers palliative and supportive care to meet the
18 special needs arising out of the physical, emotional and spiritual
19 stresses which are experienced during the final stages of illness
20 and during dying and bereavement. This care is available twenty-
21 four (24) hours a day, seven (7) days a week, and is provided on the
22 basis of need, regardless of ability to pay. “Class A” Hospice
23 refers to Medicare-certified hospices. “Class B” refers to all
24 other providers of hospice services;
Req. No. 12904 Page 28

1 25. “Imitation controlled substance” means a substance that is
2 not a controlled dangerous substance, which by dosage unit
3 appearance, color, shape, size, markings or by representations made,
4 would lead a reasonable person to believe that the substance is a
5 controlled dangerous substance, or is a drug intended solely for
6 veterinary purposes that is not a controlled dangerous substance and
7 is being used outside of the scope of practice or normal course of
8 business, as defined by the State Board of Veterinary Medical
9 Examiners, or is a federal Food and Drug Administration-approved
10 drug that is not a controlled dangerous substance and is being used
11 outside the scope of approval for illicit purposes such as
12 adulterating or lacing other controlled dangerous substances. In
13 the event the appearance of the dosage unit or use is not reasonably
14 sufficient to establish that the substance is an imitation
15 controlled substance, the court or authority concerned should
16 consider, in addition to all other factors, the following factors:
17 a. statements made by an owner or by any other person in
18 control of the substance concerning the nature of the
19 substance, or its use or effect,
20 b. statements made to the recipient that the substance
21 may be resold for inordinate profit,
22 c. whether the substance is packaged in a manner normally
23 used for illicit controlled substances,
24
Req. No. 12904 Page 29

1 d. evasive tactics or actions utilized by the owner or
2 person in control of the substance to avoid detection
3 by law enforcement authorities,
4 e. prior convictions, if any, of an owner, or any other
5 person in control of the object, under state or
6 federal law related to controlled substances or fraud,
7 and
8 f. the proximity of the substances to controlled
9 dangerous substances;
10 26. “Immediate precursor” means a substance which the Director
11 has found to be and by regulation designates as being the principal
12 compound commonly used or produced primarily for use, and which is
13 an immediate chemical intermediary used, or likely to be used, in
14 the manufacture of a controlled dangerous substance, the control of
15 which is necessary to prevent, curtail or limit such manufacture;
16 27. “Initial prescription” means a prescription issued to a
17 patient who:
18 a. has never previously been issued a prescription for
19 the drug or its pharmaceutical equivalent in the past
20 year, or
21 b. requires a prescription for the drug or its
22 pharmaceutical equivalent due to a surgical procedure
23 or new acute event and has previously had a
24
Req. No. 12904 Page 30

1 prescription for the drug or its pharmaceutical
2 equivalent within the past year.
3 When determining whether a patient was previously issued a
4 prescription for a drug or its pharmaceutical equivalent, the
5 practitioner shall consult with the patient and review the medical
6 record and prescription monitoring information of the patient;
7 28. “Isomer” means the optical isomer, except as used in
8 subsections C and F of Section 2-204 of this title and paragraph 4
9 of subsection A of Section 2-206 of this title. As used in
10 subsections C and F of Section 2-204 of this title, isomer means the
11 optical, positional, or geometric isomer. As used in paragraph 4 of
12 subsection A of Section 2-206 of this title, the term isomer means
13 the optical or geometric isomer;
14 29. “Laboratory” means a laboratory approved by the Director as
15 proper to be entrusted with the custody of controlled dangerous
16 substances and the use of controlled dangerous substances for
17 scientific and medical purposes and for purposes of instruction;
18 30. “Manufacture” means the production, preparation,
19 propagation, compounding or processing of a controlled dangerous
20 substance, either directly or indirectly by extraction from
21 substances of natural or synthetic origin, or independently by means
22 of chemical synthesis or by a combination of extraction and chemical
23 synthesis. “Manufacturer” includes any person who packages,
24 repackages or labels any container of any controlled dangerous
Req. No. 12904 Page 31

1 subs tance, except practitioners who dispense or compound
2 prescription orders for delivery to the ultimate consumer;
3 31. “Marijuana” means all parts of the plant Cannabis sativa
4 L., whether growing or not; the seeds thereof; the resin extracted
5 from any part of such plant; and every compound, manufacture, salt,
6 derivative, mixture or preparation of such plant, its seeds or
7 resin, but shall not include:
8 a. the mature stalks of such plant or fiber produced from
9 such stalks,
10 b. oil or cake made from the seeds of such plant,
11 including cannabidiol derived from the seeds of the
12 marijuana plant,
13 c. any other compound, manufacture, salt, derivative,
14 mixture or preparation of such mature stalks (except
15 the resin extracted therefrom), including cannabidiol
16 derived from mature stalks, fiber, oil or cake,
17 d. the sterilized seed of such plant which is incapable
18 of germination,
19 e. for any person participating in a clinical trial to
20 administer cannabidiol for the treatment of severe
21 forms of epilepsy pursuant to Section 2-802 of this
22 title, a drug or substance approved by the federal
23 Food and Drug Administration for use by those
24 participants,
Req. No. 12904 Page 32

1 f. for any person or the parents, legal guardians or
2 caretakers of the person who have received a written
3 certification from a physician licensed in this state
4 that the person has been diagnosed by a physician as
5 having Lennox-Gastaut syndrome, Dravet syndrome, also
6 known as severe myoclonic epilepsy of infancy, or any
7 other severe form of epilepsy that is not adequately
8 treated by traditional medical therapies, spasticity
9 due to multiple sclerosis or due to paraplegia,
10 intractable nausea and vomiting, appetite stimulation
11 with chronic wasting diseases, the substance
12 cannabidiol, a nonpsychoactive cannabinoid, found in
13 the plant Cannabis sativa L. or any other preparation
14 thereof, that has a tetrahydrocannabinol concentration
15 not more than three-tenths of one percent (0.3%) and
16 that is delivered to the patient in the form of a
17 liquid,
18 g. any federal Food and Drug Administration-approved drug
19 or substance, or
20 h. industrial hemp, from the plant Cannabis sativa L. and
21 any part of such plant, whether growing or not, with a
22 delta-9 tetrahydrocannabinol concentration not more
23 than three-tenths of one percent (0.3%) on a dry-
24 weight basis which shall only be grown pursuant to the
Req. No. 12904 Page 33

1 Oklahoma Industrial Hemp Program and may be shipped
2 intrastate and interstate;
3 32. “Medical purpose” means an intention to utilize a
4 controlled dangerous substance for physical or mental treatment, for
5 diagnosis, or for the prevention of a disease condition not in
6 violation of any state or federal law and not for the purpose of
7 satisfying physiological or psychological dependence or other abuse;
8 33. “Mid-level practitioner” means an Advanced Practice
9 Registered Nurse as defined and within parameters specified in
10 Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
11 animal euthanasia technician as defined in Section 698.2 of Title 59
12 of the Oklahoma Statutes, or an animal control officer registered by
13 the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
14 under subsection B of Section 2-301 of this title within the
15 parameters of such officer’s duties under Sections 501 through 508
16 of Title 4 of the Oklahoma Statutes;
17 34. “Narcotic drug” means any of the following, whether
18 produced directly or indirectly by extraction from substances of
19 vegetable origin, or independently by means of chemical synthesis,
20 or by a combination of extraction and chemical synthesis:
21 a. opium, coca leaves and opiates,
22 b. a compound, manufacture, salt, derivative or
23 preparation of opium, coca leaves or opiates,
24
Req. No. 12904 Page 34

1 c. cocaine, its salts, optical and geometric isomers, and
2 salts of isomers,
3 d. ecgonine, its derivatives, their salts, isomers and
4 salts of isomers, and
5 e. a substance, and any compound, manufacture, salt,
6 derivative or preparation thereof, which is chemically
7 identical with any of the substances referred to in
8 subparagraphs a through d of this paragraph, except
9 that the words narcotic drug as used in Section 2-101
10 et seq. of this title shall not include decocainized
11 coca leaves or extracts of coca leaves, which extracts
12 do not contain cocaine or ecgonine;
13 35. “Opiate” or “opioid” means any Schedule II, III, IV or V
14 substance having an addiction-forming or addiction-sustaining
15 liability similar to morphine or being capable of conversion into a
16 drug having such addiction-forming or addiction-sustaining
17 liability. The terms do not include, unless specifically designated
18 as controlled under the Uniform Controlled Dangerous Substances Act,
19 the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
20 salts (dextromethorphan). The terms do include the racemic and
21 levorotatory forms;
22 36. “Opium poppy” means the plant of the species Papaver
23 somniferum L., except the seeds thereof;
24
Req. No. 12904 Page 35

1 37. “Palliative care” means a specialized medical service for
2 people of any age and at any stage of a serious illness or life-
3 altering medical event that focuses on navigating complex medical
4 decisions while providing patient autonomy and access to
5 information. Utilizing a holistic and interdisciplinary team
6 approach, palliative care addresses physical, intellectual,
7 emotional, social, and spiritual needs. Palliative care may be
8 provided in the inpatient, outpatient, or home care setting and
9 strives to improve quality of life for both the patient and the
10 family;
11 38. “Patient-provider agreement” means a written contract or
12 agreement that is executed between a practitioner and a patient
13 prior to the commencement of treatment for chronic pain using an
14 opioid drug as a means to:
15 a. explain the possible risk of development of physical
16 or psychological dependence in the patient and prevent
17 the possible development of addiction,
18 b. document the understanding of both the practitioner
19 and the patient regarding the patient-provider
20 agreement of the patient,
21 c. establish the rights of the patient in association
22 with treatment and the obligations of the patient in
23 relation to the responsible use, discontinuation of
24 use, and storage of opioid drugs, including any
Req. No. 12904 Page 36

1 restrictions on the refill of prescriptions or the
2 acceptance of opioid prescriptions from practitioners,
3 d. identify the specific medications and other modes of
4 treatment, including physical therapy or exercise,
5 relaxation, or psychological counseling, that are
6 included as a part of the patient-provider agreement,
7 e. specify the measures the practitioner may employ to
8 monitor the compliance of the patient including, but
9 not limited to, random specimen screens and pill
10 counts, and
11 f. delineate the process for terminating the agreement,
12 including the consequences if the practitioner has
13 reason to believe that the patient is not complying
14 with the terms of the agreement. Compliance with the
15 consent items described in this paragraph shall
16 constitute a valid, informed consent for opioid
17 therapy. The practitioner shall be held harmless from
18 civil litigation for failure to treat pain if the
19 event occurs because of nonadherence by the patient
20 with any of the provisions of the patient-provider
21 agreement;
22 39. “Peace officer” means a police officer, sheriff, deputy
23 sheriff, district attorney’s investigator, investigator from the
24 Office of the Attorney General, or any other person elected or
Req. No. 12904 Page 37

1 appo inted by law to enforce any of the criminal laws of this state
2 or of the United States;
3 40. “Person” means an individual, corporation, government or
4 governmental subdivision or agency, business trust, estate, trust,
5 partnership or association, or any other legal entity;
6 41. “Poppy straw” means all parts, except the seeds, of the
7 opium poppy, after mowing;
8 42. “Practitioner” means:
9 a. (1) a medical doctor or osteopathic physician,
10 (2) a dentist,
11 (3) a podiatrist,
12 (4) an optometrist,
13 (5) a veterinarian,
14 (6) a physician assistant or an Advanced Practice
15 Registered Nurse under the supervision of a
16 licensed medical doctor or osteopathic physician,
17 or a physician assistant,
18 (7) a scientific investigator, or
19 (8) any other person,
20 licensed, registered or otherwise permitted to
21 prescribe, distribute, dispense, conduct research with
22 respect to, use for scientific purposes or administer
23 a controlled dangerous substance in the course of
24 professional practice or research in this state, or
Req. No. 12904 Page 38

1 b. a pharmacy, hospital, laboratory or other institution
2 licensed, registered or otherwise permitted to
3 distribute, dispense, conduct research with respect
4 to, use for scientific purposes or administer a
5 controlled dangerous substance in the course of
6 professional practice or research in this state;
7 43. “Production” includes the manufacture, planting,
8 cultivation, growing or harvesting of a controlled dangerous
9 substance;
10 44. “Serious illness” means a medical illness or physical
11 injury or condition that substantially affects quality of life for
12 more than a short period of time. Serious illness includes, but is
13 not limited to, Alzheimer’s disease or related dementias, lung
14 disease, cancer, heart failure, renal failure, liver failure, or
15 chronic, unremitting, or intractable pain such as neuropathic pain;
16 45. “State” means the State of Oklahoma or any other state of
17 the United States;
18 46. “Straw person” or “straw party”, also known as a “front”,
19 means a third party who:
20 a. is put up in name only to take part in a transaction
21 or otherwise is a nominal party to a transaction with
22 no actual control,
23
24
Req. No. 12904 Page 39

1 b. acts on behalf of another person to obtain title to
2 property and executes documents and instruments the
3 principal may direct respecting property, or
4 c. purchases property for another for the purpose of
5 concealing the identity of the real purchaser or to
6 accomplish some purpose otherwise in violation of the
7 Oklahoma Statutes;
8 47. “Surgical procedure” means a procedure that is performed
9 for the purpose of structurally altering the human body by incision
10 or destruction of tissues as part of the practice of medicine. This
11 term includes the diagnostic or therapeutic treatment of conditions
12 or disease processes by use of instruments such as lasers,
13 ultrasound, ionizing, radiation, scalpels, probes, or needles that
14 cause localized alteration or transportation of live human tissue by
15 cutting, burning, vaporizing, freezing, suturing, probing, or
16 manipulating by closed reduction for major dislocations or
17 fractures, or otherwise altering by any mechanical, thermal, light-
18 based, electromagnetic, or chemical means;
19 48. a. “Synthetic controlled substance” means a substance:
20 (1) the chemical structure of which is substantially
21 similar to the chemical structure of a controlled
22 dangerous substance in Schedule I or II,
23 (2) which has a stimulant, depressant, or
24 hallucinogenic effect on the central nervous
Req. No. 12904 Page 40

1 system that is substantially similar to or
2 greater than the stimulant, depressant, or
3 hallucinogenic effect on the central nervous
4 system of a controlled dangerous substance in
5 Schedule I or II, or
6 (3) with respect to a particular person, which such
7 person represents or intends to have a stimulant,
8 depressant, or hallucinogenic effect on the
9 central nervous system that is substantially
10 similar to or greater than the stimulant,
11 depressant, or hallucinogenic effect on the
12 central nervous system of a controlled dangerous
13 substance in Schedule I or II.
14 b. The designation of gamma-butyrolactone or any other
15 chemical as a precursor, pursuant to Section 2-322 of
16 this title, does not preclude a finding pursuant to
17 subparagraph a of this paragraph that the chemical is
18 a synthetic controlled substance.
19 c. Synthetic controlled substance does not include:
20 (1) a controlled dangerous substance,
21 (2) any substance for which there is an approved new
22 drug application,
23 (3) with respect to a particular person any
24 substance, if an exemption is in effect for
Req. No. 12904 Page 41

1 investigational use, for that person under the
2 provisions of Section 505 of the Federal Food,
3 Drug, and Cosmetic Act, 21 U.S.C., Section 355,
4 to the extent conduct with respect to such
5 substance is pursuant to such exemption, or
6 (4) any substance to the extent not intended for
7 human consumption before such an exemption takes
8 effect with respect to that substance.
9 d. Prima facie evidence that a substance containing
10 salvia divinorum has been enhanced, concentrated, or
11 chemically or physically altered shall give rise to a
12 rebuttable presumption that the substance is a
13 synthetic controlled substance;
14 49. “Tetrahydrocannabinols” means all substances that have been
15 chemically synthesized to emulate the tetrahydrocannabinols of
16 marijuana, specifically including any tetrahydrocannabinols derived
17 from industrial hemp; and
18 50. “Ultimate user” means a person who lawfully possesses a
19 controlled dangerous substance for the person’s own use or for the
20 use of a member of the person’s household or for administration to
21 an animal owned by the person or by a member of the person’s
22 household.
23
24
Req. No. 12904 Page 42

1 SECTION 9. AMENDATORY 63 O.S. 2021, Section 2-312, as
2 amended by Section 2, Chapter 184, O.S.L. 2022 (63 O.S. Supp. 2024,
3 Section 2-312), is amended to read as follows:
4 Section 2-312. A. A physician, podiatrist, optometrist or a
5 dentist who has complied with the registration requirements of the
6 Uniform Controlled Dangerous Substances Act, in good faith and in
7 the course of such person's professional practice only, may
8 prescribe and administer controlled dangerous substances, or may
9 cause the same to be administered by medical or paramedical
10 personnel acting under the direction and supervision of the
11 physician, podiatrist, optometrist or dentist, and only may dispense
12 controlled dangerous substances pursuant to the provisions of
13 Sections 355.1 and 355.2 of Title 59 of the Oklahoma Statutes.
14 B. A veterinarian who has complied with the registration
15 requirements of the Uniform Controlled Dangerous Substances Act, in
16 good faith and in the course of the professional practice of the
17 veterinarian only, and not for use by a human being, may prescribe,
18 administer, and dispense controlled dangerous substances and may
19 cause them to be administered by an assistant or orderly under the
20 direction and supervision of the veterinarian.
21 C. An advanced practice nurse who is recognized to prescribe by
22 the Oklahoma Board of Nursing as an advanced registered nurse
23 practitioner, clinical nurse specialist or certified nurse-midwife,
24 who is subject to medical direction by a supervising physician,
Req. No. 12904 Page 43

1 purs uant to Section 567.3a of Title 59 of the Oklahoma Statutes, and
2 who has complied with the registration requirements of the Uniform
3 Controlled Dangerous Substances Act, in good faith and in the course
4 of professional practice only, may prescribe and administer Schedule
5 III, IV and V controlled dangerous substances.
6 D. An advanced practice nurse who is recognized to order,
7 select, obtain and administer drugs by the Oklahoma Board of Nursing
8 as a certified registered nurse anesthetist pursuant to Section
9 353.1b of Title 59 of the Oklahoma Statutes and who has complied
10 with the registration requirements of the Uniform Controlled
11 Dangerous Substances Act, in good faith and in the course of such
12 practitioner's professional practice only, may order, select, obtain
13 and administer Schedules II through V controlled dangerous
14 substances in a preanesthetic preparation or evaluation; anesthesia
15 induction, maintenance or emergence; or postanesthesia care setting
16 only. A certified registered nurse anesthetist may order, select,
17 obtain and administer such drugs only during the perioperative or
18 periobstetrical period.
19 E. A physician assistant who is recognized to prescribe by the
20 State Board of Medical Licensure and Supervision under the medical
21 direction of a supervising physician, pursuant to Section 519.6 of
22 Title 59 of the Oklahoma Statutes, and who has complied with the
23 registration requirements of the Uniform Controlled Dangerous
24 Substances Act, in good faith and in the course of professional
Req. No. 12904 Page 44

1 prac tice only, may prescribe and administer Schedule II through V
2 controlled dangerous substances subject to the restrictions in
3 Section 519.6 of Title 59 of the Oklahoma Statutes.
4 SECTION 10. REPEALER 59 O.S. 2021, Section 521.4, is
5 hereby repealed.
6 SECTION 11. It being immediately necessary for the preservation
7 of the public peace, health or safety, an emergency is hereby
8 declared to exist, by reason whereof this act shall take effect and
9 be in full force from and after its passage and approval.
10
11 60-1-12904 TJ 02/25/25
12
13
14
15
16
17
18
19
20
21
22
23
24
Req. No. 12904 Page 45

[DELETED:  P B]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P b r b]
[DELETED:  P r t]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P a t]
[DELETED:  P]
[DELETED:  P r]
[DELETED:  P i o i k]
[DELETED:  P k i t s d s]
[DELETED:  P b c c h o m]
[DELETED:  P w c s r m c c e a a]
[DELETED:  P r r i]
[DELETED:  P]
[DELETED:  P s s w]
[DELETED:  P e p t h r]
[DELETED:  P]
[DELETED:  P t o a t f]
[DELETED:  P f a i]
[DELETED:  P o a]
[DELETED:  P c e a]
[DELETED:  P e d e]
[DELETED:  P i s d]
[DELETED:  P ( a a a a a a a a]
[DELETED:  P a i]
[DELETED:  P a p a “ t w]
[DELETED:  P w T S a a w]
[DELETED:  P a P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P T 0]